United States Office of Water EPA- 820R15104
hvu Environmental Mail Code 4304T June 2015
m JF LaiWik Protection Agency
Health Effects Support Document
for the Cyanobacterial Toxin
Anatoxin-A
-------
Health Effects Support Document
for the Cyanobacterial Toxin
Anatoxin-A
U.S. Environmental Protection Agency
Office of Water (4304T)
Health and Ecological Criteria Division
Washington, DC 20460
EPA Document Number: 820R15104
Date: June 15, 2015
-------
FOREWORD
The Safe Drinking Water Act (SDWA), as amended in 1996, requires the Administrator of
the U.S. Environmental Protection Agency (EPA) to establish a list of unregulated
microbiological and chemical contaminants that are known or anticipated to occur in public water
systems and that may need to be controlled with a national primary drinking water regulation. The
SDWA also requires that the Agency make regulatory determinations on at least five
contaminants on the list every five years. For each contaminant on the Contaminant Candidate
List (CCL), the Agency will need to obtain sufficient data to conduct analyses on the extent of
occurrence and the risk posed to populations via drinking water. Ultimately, this information will
assist the Agency in determining the appropriate course of action (e.g., develop a regulation,
develop guidance or make a decision not to regulate the contaminant in drinking water).
This document presents information, including occurrence, toxicology and epidemiology
data, for the cyanobacterial toxin anatoxin-a to be considered in the development of a Drinking
Water Health Advisory (DWHA). DWHAs serve as the informal technical guidance for
unregulated drinking water contaminants to assist federal, state and local officials, and managers
of public or community water systems in protecting public health as needed. They are not to be
construed as legally enforceable federal standards.
To develop the Health Effects Support Document (HESD) for anatoxin-a, a
comprehensive literature search was conducted from January 2013 to May 2014 using Toxicology
Literature Online (TOXLINE), PubMed component, and Google Scholar to ensure the most
recent published information on anatoxin-a was included in this document. The literature search
included the following terms: anatoxin-a, human toxicity, animal toxicity, in vitro toxicity, in vivo
toxicity, occurrence, environmental fate, mobility, and persistence. EPA assembled available
information on occurrence; environmental fate; mechanisms of toxicity; acute, short term,
subchronic and chronic toxicity and cancer in humans and animals; toxicokinetics; and exposure.
Additionally, EPA relied on information from the following risk assessments in the development
of the anatoxin-a's HESD:
• Health Canada (2012) Toxicity Profile for Cyanobacterial Toxins
• Enzo Funari and Emanuela Testai (2008) Human Health Risk Assessment Related to
Cyanotoxins Exposure
• Tai Nguyen Duy, Paul Lam, Glen Shaw and Des Connell (2000) Toxicology and Risk
Assessment of Freshwater Cyanobacterial (Blue-Green Algal) Toxins in Water
Development of the HESD for anatoxin-a follows the general guidelines for risk
assessment as set forth by the National Research Council (1983) and EPA's (2014) Framework
for Human Health Risk Assessment to Inform Decision Making. EPA guidelines that were used in
the development of this assessment include the following:
• Guidelines for the Health Risk Assessment of Chemical Mixtures (U.S. EPA, 1986a)
• Guidelines for Mutagenicity Risk Assessment (U.S. EPA, 1986b)
Health Effects Support Document for Anatoxin-a - June 2015
in
-------
• Recommendations for and Documentation of Biological Values for Use in Risk Assessment
(U.S. EPA, 1988)
• Guidelines for Developmental Toxicity Risk Assessment (U.S. EPA, 1991)
• Interim Policy for Particle Size and Limit Concentration Issues in Inhalation Toxicity
Studies (U.S. EPA, 1994a)
• Methods for Derivation of Inhalation Reference Concentrations and Application of
Inhalation Dosimetry (U.S. EPA, 1994b)
• Use of the Benchmark Dose Approach in Health Risk Assessment (U. S. EPA, 1995)
• Guidelines for Reproductive Toxicity Risk Assessment (U.S. EPA, 1996)
• Guidelines for Neurotoxicity Risk Assessment (U. S. EPA, 1998)
• Science Policy Council Handbook. Peer Review (2nd edition) (U.S. EPA, 2000a)
• Supplemental Guidance for Conducting Health Risk Assessment of Chemical Mixtures
(U.S. EPA, 2000b)
• A Review of the Reference Dose and Reference Concentration Processes (U.S. EPA,
2002)
• Guidelines for Carcinogen Risk Assessment (U.S. EPA, 2005a)
• Supplemental Guidance for Assessing Susceptibility from Early-Life Exposure to
Carcinogens (U.S. EPA, 2005b)
• Science Policy Council Handbook: Peer Review (U.S. EPA, 2006a)
• A Framework for Assessing Health Risks of Environmental Exposures to Children (U. S.
EPA, 2006b)
• Exposure Factors Handbook 2011 Edition (U.S. EPA, 201 1)
• Benchmark Dose Technical Guidance Document (U.S. EPA, 2012)
• Child-Specific Exposure Scenarios Examples (U.S. EPA, 2014a)
• Framework for Human Health Risk Assessment to Inform Decision Making (U. S. EPA,
2014b)
iv
Health Effects Support Document for Anatoxin-a - June 2015
-------
AUTHORS, CONTRIBUTORS AND REVIEWERS
Authors
Lesley V. D'Anglada, Dr.P.H. (Lead)
Joyce M. Donohue, Ph.D.
Jamie Strong, Ph.D.
Office of Water, Office of Science and Technology
Health and Ecological Criteria Division
U.S. Environmental Protection Agency, Washington, DC
Belinda Hawkins, Ph.D., DABT
Office of Research and Development, National Center for Environmental Assessment
U.S. Environmental Protection Agency, Cincinnati, OH
The following contactor authors supported the development of this document:
Anthony Q. Armstrong, M.S.
Carol S. Wood, Ph.D., DABT
Oak Ridge National Laboratory, Oak Ridge, TN
The Oak Ridge National Laboratory is managed and operated by UT-Battelle, LLC. for the U.S.
Department of Energy under Contract No. DE-AC05-00OR22725.
The following contractor authors developed earlier unpublished drafts that contributed
significantly to this document:
Carrie Fleming, Ph.D. (former Oak Ridge Institute for Science and Education participant)
Oak Ridge National Laboratory, Oak Ridge, TN
Stephen Bosch, B.S.
Marc Odin, M.S., DABT
David Wohlers, Ph.D.
SRC, Inc., Syracuse, NY
Robyn Blain, Ph.D.
Audrey Ichida, Ph.D.
Kaedra Jones, MPH
William Mendez, Ph.D.
Pam Ross, MPH
ICF International, Fairfax, VA
Reviewers
Internal Peer Reviewers
Neil Chernoff, Ph.D. Office of Research and Development, U.S. EPA
v
Health Effects Support Document for Anatoxin-a - June 2015
-------
Armah A. de la Cruz, Ph.D.
Elizabeth Hilborn, DVM, MPH, DACVPM
Heath Mash, Ph.D.
Nicole Shao, M.S.
Jody Shoemaker, Ph.D.
External Peer Reviewers
Lorraine Backer, Ph.D., MPH
Wayne W. Carmichael, Ph.D.
Richard Charron, M.S.
Michele Giddings, B.S.
Ian Stewart, Ph.D.
Office of Research and Development, U.S. EPA
Office of Research and Development, U.S. EPA
Office of Research and Development, U.S. EPA
Office of Research and Development, U.S. EPA
Office of Research and Development, U.S. EPA
Centers for Disease Control and Prevention
Wright State University
Water and Air Quality Bureau, Health Canada
Water and Air Quality Bureau, Health Canada
South Australian Government's R&D Institute
(SARDI)
vi
Health Effects Support Document for Anatoxin-a - June 2015
-------
TABLE OF CONTENTS
FOREWORD Ill
TABLE OF CONTENTS VII
LIST OF TABLES IX
LIST OF FIGURES IX
ABBREVIATIONS AND ACRONYMS X
EXECUTIVE SUMMARY 1
1.0 IDENTITY: CHEMICAL AND PHYSICAL PROPERTIES 3
2.0 TOXIN SYNTHESIS AND ENVIRONMENTAL FATE 6
2.1 Cyanotoxin Synthesis 6
2.2 Environmental Factors that Affect the Fate of Cyanotoxins 6
2.2.1 Nutrients 6
2.2.2 Light Intensity 7
2.2.3 T emperature 7
2.2.4 Other Environmental Factors 8
2.3 Environmental Fate of Anatoxin-a 10
2.3.1 Hydrolysis 10
2.3.2 Photolysis 10
2.3.3 Metabolism 11
2.3.4 Transport 11
2.4 Summary 11
3.0 CYANOTOXIN OCCURRENCE AND EXPOSURE IN WATER 12
3.1 General Occurrence of Cyanobacteria in Water 12
3.2 Anatoxin-a Occurrence in Surface Water 12
3.3 Anatoxin-a Occurrence in Drinking Water 14
4.0 OCCURRENCE IN MEDIA OTHER THAN WATER 15
4.1 Occurrence in Soil and Edible Plants 15
4.2 Occurrence in Fish and Shellfish 15
4.3 Occurrence in Dietary Supplements 16
5.0 TOXICOKINETICS 17
5.1 Absorption 17
5.2 Distribution 17
5.3 Metabolism 17
5.4 Excretion 17
5.5 Pharmacokinetic Considerations 17
6.0 HAZARD IDENTIFICATION 18
6.1 Case Reports and Epidemiology Studies 18
6.2 Animal Studies 18
6.2.1 Acute Toxicity 18
vii
Health Effects Support Document for Anatoxin-a - June 2015
-------
6.2.1.1 Oral Exposure 18
6.2.1.2 Other Exposure Routes 19
6.2.2 Short Term Studies 20
6.2.3 Subchronic Studies 20
6.2.3.1 Oral Exposure 20
6.2.3.2 Other Exposure Routes 21
6.2.4 Chronic Toxicity 25
6.3 Carcinogenicity 25
6.4 Other Key Data 25
6.4.1 Mutageni city and Genotoxi city 25
6.4.2 Immunotoxicity 25
6.5 Physiological or Mechanistic Studies 26
6.5.1 Noncancer Effects 26
6.5.2 Cancer Effects 26
6.5.3 Interactions with Other Chemicals 27
6.5.4 Structure Activity Relationship 27
6.6 Hazard Characterization 28
6.6.1 Synthesis and Evaluation of Major Noncancer Effects 28
6.6.2 Synthesis and Evaluation of Major Carcinogenic Effects 29
6.6.2.1 Mode of Action and Implications in Cancer Assessment 29
6.6.2.2 Weight of Evidence Evaluation for Carcinogenicity 29
6.6.2.3 Potentially Sensitive Populations 29
7.0 DOSE-RESPONSE ASSESSMENT 30
7.1 Dose-Response for Noncancer Effects 30
7.1.1 RfD Determination 30
7.1.2 RfC Determination 31
7.2 Dose-Response for Cancer Effects 31
8.0 RESEARCH GAPS 32
9.0 REFERENCES 33
viii
Health Effects Support Document for Anatoxin-a - June 2015
-------
LIST OF TABLES
Table 1-1. Chemical and Physical Properties of Anatoxin-a 5
LIST OF FIGURES
Figure 1-1. Structures of Anatoxin-a and Homoanatoxin-a (Mann et al., 2011) 4
Figure 2-1. Environmental factors influencing cyanobacterial blooms 10
Health Effects Support Document for Anatoxin-a - June 2015
IX
-------
ABBREVIATIONS AND ACRONYMS
ADHD
Attention deficit hyperactivity disorder
AFA
Aphanizomenon flos-aquae
ALP
alkaline phosphatase
AMPHITOX
Amphibian Embryo-Larval Toxicity Test
AST
Aspartate aminotransferase
ATP
Adenosine triphosphate
BGAS
Bluegreen algae supplements
CAS
Chemical Abstracts Service
CCL
Contaminant Candidate List
CDC
Centers for Disease Control
CE
CI
Confidence Interval
CNS
Central Nervous System
DNA
Deoxyribonucleic Acid
DWHA
Drinking Water Health Advisories
ED50
Median effective dose
ELISA
Enzyme-linked Immunosorbent assay
EPA
U.S. Environmental Protection Agency
FEL
Frank effect level
g
Gram
GD
Gestation day
HA
Health Advisory
HAB
Harmful algal bloom
HESD
Health Effects Support Document
HPLC
High Pressure Liquid Chromatography
HPLC/FD
High Pressure Liquid Chromatography Fluorescence Detection
ILS
Integrated Laboratory Systems
i.p.
Intraperitoneal
kg
Kilogram
Kow
Octanol:water partition coefficient
Koc
Organic carbon:water partition coefficient
L
Liter
LC-MS/MS
Liquid chromatography tandem mass spectrometry
LD50
Lethal doseso
LOAEL
Lowest-ob served-adverse-effect level
LPS
Lipopolysaccharides
Hg
Microgram
|iM
Micromole
mg
Milligram
mL
Milliliter
N
Nitrogen
N/A
Not Applicable
ng
Nanogram
NOAEL
No-observed-adverse-effect level
x
Health Effects Support Document for Anatoxin-a - June 2015
-------
p
Phosphorus
PND
Postnatal days
RBC
Red blood cell
RfD
Reference dose
SDWA
Safe Drinking Water Act
TOXLINE
Toxicology Literature Online
USGS
U.S. Geological Survey
WHO
World Health Organization
WSDE
Washington State Department of Ecology
Health Effects Support Document for Anatoxin-a - June 2015
XI
-------
EXECUTIVE SUMMARY
The U.S. Environmental Protection Agency (EPA) has prepared this Health Effects
Support Document (HESD) for anatoxin-a to be considered in developing a Health Advisory
(HA). The available data on toxicity are not adequate to derive a health-based value for anatoxin-
a at the present time. EPA will reevaluate the ability to derive an HA for anatoxin-a as new
information becomes available.
Anatoxin-a is produced by a variety of cyanobacteria species including: Chrysosporum
(Aphanizomenon) ovalisporum, Cuspidothrix, Cylindrospermopsis, Cylindrospermum,
Dolichospermum, Microcystis, Oscillatoria, Planktothrix, Phormidium, Anabaena flos-aquae, A.
lemmermannii Raphidiopsis mediterranea (strain of Cylindrospermopsis raciborskii),
Tychonema and Woronichinia (Funari and Testai, 2008; Moustaka-Gouni et al., 2009).
Anatoxin-a is weakly sorbed to sandy sediments and sorbs most strongly to clay-rich and
organic-rich sediment (Klitzke et al., 2011). Anatoxin-a undergoes rapid photochemical
degradation in sunlight, with higher pH favoring degradation reactions (Stevens and Krieger,
1991a). A half-life of 1 to 2 hours at pH ranges from 8 to 9 have been reported. In the absence of
sunlight, half-lives of anatoxin-a can range from several days to several months (Stevens and
Krieger, 1991a).
Anatoxin-a is highly soluble in water and has been found in surface waters around the
world including the U.S. Limited information is available on anatoxin-a in finished drinking
water, and reported concentrations are rare and vary widely depending on the water body
sampled and the analytical method used.
Deaths in domestic animals, livestock and waterfowl that consumed water containing
cyanotoxins including anatoxin-a from cyanobacteria blooms have been reported. The signs of
toxicity were mostly neurologic, with deaths due to respiratory paralysis. Very limited
information was available on anatoxin-a accumulation in plants and fish.
No quantitative data were located regarding the rate or extent of absorption, tissue
distribution, metabolism or excretion of anatoxin-a in humans or animals. In oral toxicity studies,
animals demonstrated acute clinical signs of neurotoxicity such as loss of coordination, muscular
twitching and death from respiratory paralysis within several minutes of exposure (Stevens and
Krieger, 1991a; Fitzgeorge et al., 1994). Based on these studies, anatoxin-a is rapidly absorbed
from the gastrointestinal tract and distributed in the blood.
Literature on the toxicity from oral exposure to anatoxin-a is limited and the majority of
studies are in vitro experimental studies on its mode of neurotoxic action. These studies have
established that anatoxin-a binds to acetylcholine receptors and mimics the action of
acetylcholine at neuromuscular nicotinic receptors which causes neurological effects (Wonnacott
and Gallagher, 2006). With sufficient exposure, acetylcholine accumulation occurs at skeletal
myoneural junctions, at cholinergic neuroeffector junctions (muscarinic effects) and in
autonomic ganglia (nicotinic effects).
Health Effects Support Document for Anatoxin-a - June 2015
1
-------
Information on the short-term oral toxicity of anatoxin-a is available from 5-day and 28-
day systemic toxicity studies in mice, and a developmental toxicity study in mice (Fawell and
James, 1994; Fawell et al., 1999). A NOAEL (No Observed Adverse Effect Level) of 0.1 mg/kg-
day was derived from the 28-day study that tested groups of 10 mice per sex at dose levels of 0,
0.1, 0.5 and 2.5 mg/kg-day. The study demonstrated mortality at doses >0.5 mg/kg-day since one
of 10 animals died in each of the two highest dose groups at days 10 and 14 of dosing,
respectively. The authors could not identify the cause of death for the animals that died. Other
effects reported in treated animals, such as minor changes in hematology and blood chemistry,
were not considered toxicologically significant by the authors. Therefore, these findings are not
considered sufficient to support derivation of a short-term oral reference dose (RfD) for
anatoxin-a.
One seven-week drinking water study in rats provides information on the subchronic oral
toxicity of anatoxin-a (Astrachan and Archer, 1981; Astrachan et al., 1980). The authors
identified a NOAEL of 0.05 mg/kg-day with a LOAEL (Lowest Observed Adverse Effect Level)
of 0.5 mg/kg-day for increased white blood cell counts that persisted for 5 weeks. There were no
effects on red cell counts. This study was limited because it only included two dose levels,
evaluated only a few endpoints, provided limited quantitative data, and used partially purified
extract. The toxicological significance of the increased white cell count is also unclear. Fawell et
al. (1999) reported minor, statistically significant changes in red blood cell hemoglobin and
mean cell hemoglobin concentrations at a LOAEL of 0.5 mg/kg-day, but considered them to lack
toxicological significance.
Because neither the mortality in the Fawell et al. (1999) study nor the white blood cell
end point in Astrachan and Archer (1981) were replicated in other studies, the data do not
support derivation of an RfD.
There are no data available to evaluate the carcinogenicity of anatoxin-a in humans.
Additionally, there is no dose-response or mode of action information available regarding the
carcinogenicity of anatoxin-a from studies in animals. Thus, available data do not support
assessment of the carcinogenic potential of anatoxin-a at this time.
2
Health Effects Support Document for Anatoxin-a - June 2015
-------
1.0 IDENTITY: CHEMICAL AND PHYSICAL PROPERTIES
Cyanobacteria, formerly known as blue-green algae (Cyanophyceae), are a group of
bacteria containing chlorophyll-a that can carry out the light and dark phases of photosynthesis
(Castenholz and Waterbury, 1989). In addition to chlorophyll-a, other pigments such as carotene,
xanthophyll, blue c phycocyanin and red c phycoerythrin are also present in cyanobacteria (Duy
et al., 2000). Most cyanobacteria are aerobic photoautotrophs, requiring only water, carbon
dioxide, inorganic nutrients and light for survival, but others have heterotrophic properties and
can survive long periods in complete darkness (Fay, 1965). Some species also are capable of
nitrogen fixation (i.e., diazotrophy) (Duy et al., 2000) producing inorganic nitrogen compounds
to synthesize nitrogen-containing biomolecules, such as nucleic acids and proteins.
Cyanobacteria can form symbiotic associations with animals and plants, such as fungi,
bryophytes, pteriodophytes, gymnosperms and angiosperms, supporting their growth and
reproduction (Sarma, 2013; Hudnell, 2008; Hudnell, 2010; Rai, 1990).
Cyanobacteria can be found in unicellular, colony and multicellular filamentous forms.
The unicellular form occurs when the daughter cells separate after binary fission reproduction.
These cells can aggregate into irregular colonies held together by a slimy matrix secreted during
colony growth (WHO, 1999). The filamentous form occurs when repeated cell divisions happen
in a single plane at right angles to the main axis (WHO, 1999). Reproduction is asexual.
Cyanobacteria are considered gram-negative, even though the peptidoglycan layer is
thicker than most gram-negative bacteria. However, studies using electron microscopy show that
cyanobacteria possess properties of both gram-negative and gram-positive bacteria (Stewart et
al., 2006). Compared to heterotrophic bacteria, the cyanobacterial lipopolysaccharides (LPS)
have little or no 2-keto-3-deoxy-D-manno-octonic acid, and they lack phosphate groups,
glucosamine and L-glycero-D-mannoheptose. Cyanobacteria also have long-chain saturated and
unsaturated fatty acids.
Under the optimal pH, nutrient availability, light and temperature conditions,
cyanobacteria can reproduce quickly forming a bloom. Studies of the impact of environmental
factors on cyanotoxin production are ongoing, including such factors as nutrient (nitrogen,
phosphorus and trace metals) concentrations, light, temperature, oxidative stressors and
interactions with other biota (viruses, bacteria and animal grazers), as well as the combined
effects of these factors (Paerl and Otten 2013 a; 2013b). Fulvic and humic acids also have been
reported to encourage cyanobacteria growth (Kosakowska et al., 2007).
Cyanobacteria can produce a wide range of bioactive compounds, some of which have
beneficial or therapeutic effects. These bioactive compounds have been used in pharmacology, as
dietary supplements and as mood enhancers (Jensen et al., 2001). Other cyanobacteria can
produce bioactive compounds that may be harmful, called cyanotoxins. The most commonly
recognized bioactive compounds produced by cyanobacteria fall into four broad groupings:
cyclic peptides, alkaloids, amino acids and LPS. Anatoxin-a is in the alkaloid group (WHO,
1999).
Health Effects Support Document for Anatoxin-a - June 2015
3
-------
Anatoxin-a is produced by a variety of cyanobacteria species including: Chrysosporum
(Aphanizomenon) ovalisporum, Cuspidothrix, Cylindrospermopsis, Cylindrospermum,
Dolichospermum, Microcystis, Oscillatoria, Planktothrix, Phormidium, Anabaena flos-aquae, A.
lemmermannii Raphidiopsis mediterranea (strain of Cylindrospermopsis raciborskii),
Tychonema and Woronichinia (Funari and Testai, 2008; Moustaka-Gouni et al., 2009).
Anatoxin-a, or 2-acetyl-9-azbicyclo[4:2:l]non-2-ene, is a tropane-related bicyclic alkaloid (Duy
et al., 2000). Figure 1-1 shows the presence of an additional methyl group (CH) on carbon atom
11 (CI 1) differentiates anatoxin-a from its analog homoanatoxin-a. Both molecules share almost
identical toxicological properties (Funari and Testai, 2008). Other derivatives of anatoxin-a have
been identified in cyanobacteria cultures or in field samples, including 2,3-epoxy-anatoxin-a, 4-
hydroxy- and 4-oxo-derivatives, dihydroanatoxin-a and dihydrohomoanatoxin-a (Namikoshi et
al., 2003; Mann et al., 2012). Although frequently non-toxic, some of these variants may become
toxic when bound to the nicotinic acetylcholine receptor (Mann et al., 2012).
Figure 1-1. Structures of Anatoxin-a and Homoanatoxin-a (Mann et al., 2011)
Table 1-1 below provides the chemical and physical properties of anatoxin-a. It has a
molecular formula of C10H15NO and a molecular weight of 165.23 g/mole (Lewis, 2000).
Anatoxin-a is highly soluble in water and has a high boiling point of 291°C. It has a density of
1.04 g/cm3 and a low vapor pressure of 0.002 mmHg. Other physico-chemical properties such as
the soil (Koc) and living organism's adsorption (Kow) coefficients, and how it volatizes from
water and is distributed in the atmosphere (Henry's Law constant) are unknown. Limited
information on the chemical breakdown, biodegradation and distribution in the environment is
available and is discussed in the Environmental Fate Section (2.3).
H
H
4
(+>-Anatoxin-a
Homoanatoxln-a
4
Health Effects Support Document for Anatoxin-a - June 2015
-------
Table 1-1. Chemical and Physical Properties of Anatoxin-a
Property
Analoxin-a
Chemical Abstracts Service (CAS)
Registry #
64285-06-9
Chemical Formula
C10H15NO
Molecular Weight
165.23 g/mole
Color/Physical State
lyophilized solid
Boiling Point
291°C at 760 mmHg
Melting Point
N/A
Density
1.037 g/cm3
Vapor Pressure at 25°C
0.002 mmHg
Henry's Law Constant
N/A
Kow
N/A
Koc
N/A
Solubility in Water
Highly
Sources: Chemical Book, 2012; TOXLINE, 2012
Health Effects Support Document for Anatoxin-a - June 2015
5
-------
2.0 TOXIN SYNTHESIS AND ENVIRONMENTAL FATE
2.1 Cyanotoxin Synthesis
Toxin production varies between blooms and within an individual bloom over time (Duy
et al., 2000). Cyanotoxins can be produced by more than one species of cyanobacteria and some
species may produce more than one toxin at a time, resulting in blooms with different
cyanotoxins (Funari and Testai, 2008). The toxicity of a particular bloom is complex, determined
by the mixture of species and the variation of strains with toxic and nontoxic genotypes involved
(WHO, 1999). Generally, toxins in cyanobacteria are retained within the cell unless conditions
favor cell wall lysis (ILS, 2000).
Mann et al. (2012) identified the ana genes as the gene cluster responsible for the
biosynthesis of anatoxin-a and homoanatoxin-a. These analogs are formed by methylation
(corresponding to the C12 methyl group) of an intermediate tethered to the polyketide synthase
AnaG. However, the mechanism responsible for the difference in ratio of the concentration of
anatoxin-a over homoanatoxin-a has not yet been described.
2.2 Environmental Factors that Affect the Fate of Cyanotoxins
Cyanotoxin concentrations depend on the dominance and diversity of strains within the
bloom along with environmental and ecosystem influences on bloom dynamics as shown in
Figure 2-1 below (Hitzfeld et al., 2000; WHO, 1999). Cyanotoxin production is strongly
influenced by the environmental conditions that promote growth of particular cyanobacterial
species and strains. Nutrient concentrations, light intensity, temperature, and other environmental
factors affect growth and the population dynamics of cyanobacteria production, as described
below. Although environmental conditions affect the formation of blooms, the number of
cyanobacteria and the concentration of toxins produced are not always closely related.
2.2.1 Nutrients
Nutrient concentrations are key environmental drivers that influence the proportion of
cyanobacteria in the phytoplankton community, the cyanobacterial biovolume, toxin production,
and the impact that cyanobacteria may have on ecosystem function and water quality.
Cyanobacteria production and toxin concentrations are dependent on nutrient levels (Wang et al.,
2002); however, different cyanobacteria species use organic and inorganic nutrient forms
differently. Loading of nitrogen (N) and/or phosphorus (P) to water bodies from agricultural,
industrial and urban sources influence the development of cyanobacterial blooms and may be
related to cyanotoxin production (Paerl et al., 2011).
Smith (1983) first described a strong relationship between the relative amounts of N and
P in surface waters and cyanobacterial blooms. Smith proposed that cyanobacteria should be
superior competitors under conditions of N-limitation because of their unique capacity for N-
fixation. While the dominance of N-fixing cyanobacteria at low N:P ratios has been
demonstrated in mesocosm- and ecosystem-scale experiments in prairie and boreal lakes
(Schindler et al., 2008, and references therein), the hypothesis has been debated and challenged
Health Effects Support Document for Anatoxin-a - June 2015
6
-------
for its inability to reliably predict cyanobacterial dominance (Downing et al., 2001). Eutrophic
systems already subject to bloom events are prone to further expansion of these blooms due to
additional N inputs, especially if these nutrients are available from internal sources. Recent
surveys of cyanobacterial and algal productivity in response to nutrient pollution across
geographically diverse eutrophic lakes, reservoirs, estuarine and coastal waters, and in different
experimental enclosures of varying sizes demonstrate that greater stimulation is routinely
observed in response to both N and P additions. Further, this evidence suggests that nutrient
colimitation is widespread (Elser et al., 2007; Lewis et al., 2011; Paerl et al., 2011). These results
strongly suggest that reductions in both N and P inputs are needed to stem eutrophication and
cyanobacterial bloom expansion.
2.2.2 Light Intensity
Sunlight availability and turbidity have a strong influence on the cyanobacteria species
that predominate, as well as the depth at which they occur (Falconer et al., 2005; Carey et al.,
2012). For example, Cylindrospermopsis forms dense layers of filaments at the lower bound of
the euphotic zone in deeper rivers, lakes and reservoirs. The relationship of light intensity to
toxin production in blooms is somewhat unclear and continues to be investigated (Duy et al.,
2000). Some scientists have found evidence that toxin production increases with high light
intensity (Watanabe and Oishi, 1985), while others have found little variation in toxicity at
different levels of light intensity (Codd and Poon, 1988; Codd, 1995). Deep water mixing and
low light also have been associated with an increase in dominance of C. raciborskii, a toxin-
producing species (O'Brien et al., 2009).
Recently, Kosten et al. (2011) reported results from a survey of 143 lakes along a
latitudinal transect (between 5-55°S and 38-68°N) ranging from subarctic Europe to southern
South America. They found that the percentage, or biovolume, of the total phytoplankton
attributable to cyanobacteria was greater in lakes with high rates of light absorption. Kosten et al.
(2011) could not establish cause and effect from these field data; however, other controlled
experiments and field data support the importance of light availability on the competitive balance
among a large group of shade-tolerant cyanobacteria species, mainly Oscillatoriales and other
phytoplankton species (Smith, 1986; Scheffer et al., 1997). Results from Kosten et al. (2011)
also suggest that higher temperatures can interact with nutrient loading and underwater light
conditions to determine the proportion of cyanobacteria in the phytoplankton community in
shallow lakes.
2.2.3 Temperature
The increasing body of laboratory and field data (Weyhenmeyer, 2001; Huisman et al.,
2005; Reynolds, 2006; De Senerpont Domis et al., 2007; Jeppesen et al., 2009; Wagner and
Adrian, 2009; Kosten et al., 2011; Carey et al., 2012) suggest that an increase in temperature
may influence cyanobacterial dominance in the phytoplankton community. Kosten et al. (2011)
demonstrated that during the summer, the percentage of the total phytoplankton biovolume
attributable to cyanobacteria increased steeply with temperature in shallow lakes sampled along a
latitudinal transect ranging from subarctic Europe to southern South America.
Health Effects Support Document for Anatoxin-a - June 2015
7
-------
The relationship between temperature and cyanobacterial dominance may be explained in
part by the competitive advantage of cyanobacteria under higher temperatures. Warmer
temperatures favor surface bloom-forming cyanobacteria genera because they are heat-adapted
and their maximal growth rates occur at relatively high temperatures, often in excess of 25°C
(Robarts and Zohary 1987; Reynolds, 2006). At these elevated temperatures, cyanobacteria
routinely out-compete eukaryotic algae (Elliott, 2010; Paerl et al., 2011). Specifically, as the
growth rates of the eukaryotic taxa decline in response to warming, cyanobacterial growth rates
reach their optima.
Another possible factor favoring cyanobacteria with higher temperatures is based on a set
of temperature-induced mechanisms that alter underwater light levels favorably for
cyanobacteria (Kosten et al., 2011; Carey et al., 2012).
Indirectly, warming within the water column may increase nutrient concentrations by
enhancing the rate of mineralization (Gudasz et al., 2010; Kosten et al., 2009, 2010) and by
temperature or anoxia-mediated sediment phosphorus release (Jensen and Andersen, 1992;
S0ndergaard et al., 2003). Thus, temperature may increase cyanobacteria biomass indirectly
through its effect on nutrient concentrations. Others have suggested that warmer conditions may
raise total phytoplankton biomass through an alteration of top-down regulation by grazers
(Jeppesen et al., 2009, 2010; Teixeira-de Mello et al., 2009).
Rising global temperatures and changing precipitation patterns both stimulate
cyanobacteria blooms. Warmer surface waters, especially in areas of reduced precipitation, are
prone to intense vertical stratification. The degree of vertical stratification depends on the density
difference between the warm surface layer and the underlying cold water. The density difference
also is influenced by the relative amount of precipitation. As temperatures rise due to climate
change, waters are expected to stratify earlier in the spring and the stratification will persist
longer into the fall (Paerl and Otten, 2013b). The increase in water column stability associated
with higher temperatures also may favor cyanobacteria (Wagner and Adrian, 2009; Carey et al.,
2012).
2.2.4 Other Environmental Factors
Cyanobacterial blooms have been shown to intensify and persist at pH levels between six
and nine (WHO, 2003). When blooms are massive or persist for a prolonged period they can
become harmful. Kosten et al. (2011) noted the impact of pH on cyanobacteria abundance in
lakes along a latitudinal transect from Europe to southern South America. The percentage of
cyanobacteria in the 143 shallow lakes sampled was well correlated with pH, with an increased
proportion of cyanobacteria at higher pH.
Cyanobacteria have a competitive advantage over other phytoplankton species because
they are efficient users of carbon dioxide (Shapiro, 1984; Caraco and Miller, 1998). This
characteristic is especially advantageous for cyanobacteria under conditions of higher pH when
the concentration of carbon dioxide in the water column is diminished due to photosynthetic
activity. Although this could explain the positive correlation observed between pH and the
proportion of cyanobacteria, the high proportion of cyanobacteria at high pH could be the result
of an indirect nutrient effect as described previously (see discussion in Temperature Section
Health Effects Support Document for Anatoxin-a - June 2015
8
-------
2.2.3). As photosynthesis intensifies, pH increases due to carbon dioxide uptake from the water.
Thus, higher water column pH may be correlated with a higher proportion of cyanobacteria
because of higher photosynthetic rates, which can be linked with high nutrient concentrations
(Duy et al., 2000) that stimulate phytoplankton growth and bloom formation.
Most phytoplankton-cyanobacteria blooms occur in late summer and early fall when
deeper lakes or reservoirs are vertically stratified and phytoplankton species may be stratified as
well. Vertical phytoplankton biomass structure and cyanotoxin production can be influenced by
seasonal changes as well as severe weather conditions (e.g., strong wind or rainfall), and also by
runoff. At times, the hypolimnion (bottom layer of the water column) can have a higher
phytoplankton-cyanobacteria biomass and display different population dynamics than the
epilimnion (upper layer of the water column). Conversely, seasonal effects of increasing
temperatures and changes in wind patterns may favorably influence the upper water column
cyanobacterial community. This vertical variability is common and attributed to four causes,
each of which may occur at different times, including: (a) sinking of dead/dying cells; (b) density
stratification of the water column, especially nutrient concentrations and light, which affects all
aspects of cyanobacteria growth; (c) increased nutrient supply from organic-rich bottom
sediment (even when the water body is not density-stratified), encouraging cyanobacteria growth
at or near the bottom sediment; and (d) species-specific factors (Drake et al., 2010). In addition,
there are microbial interactions that may occur within blooms, such as competition and
adaptation between toxic and nontoxic cyanobacterial strains, as well as impacts from viruses.
Each of these factors can cause fluctuations in bloom development and composition. When the
composition of the cyanobacteria bloom changes, so do the toxins present and their
concentrations (Honjo et al., 2006; Paerl and Otten, 2013b). The concentration of cyanotoxins
observed in a water body when a bloom collapses, such as from cell aging or algaecide
treatment, depends on dilution of the toxin due to water column mixing, the degree of adsorption
to sediment or particulates and the rate of toxin biodegradation (Funari and Testai, 2008).
In summary, there is a complex interplay of environmental factors that dictates the spatial
and temporal changes in the concentration of cyanobacteria cells and their toxins with respect to
the dominant species as illustrated in Figure 2-1 (Paerl and Otten, 2013b). Factors such as the
N:P ratio, organic matter availability, temperature, and light attenuation, as well as other
physico-chemical processes, can play a role in determining harmful algal bloom (HAB)
composition and toxin production (Paerl and Huisman, 2008; Paerl and Otten, 2013b). Dynamics
of microflora competition as blooms develop and collapse can also impact cyanotoxin
concentrations in surface waters. In addition, impacts of climate change, including potential
warming of surface waters and changes in precipitation, could result in changes in ecosystem
dynamics that lead to more frequent formation of cyanobacteria blooms and their associated
toxins (Paerl and Huisman, 2008; Paerl et al., 2011; Paerl and Otten, 2013b).
9
Health Effects Support Document for Anatoxin-a - June 2015
-------
Figure 2-1. Environmental factors influencing cyanobacterial blooms
(Reproduced from Paerl and Otten, 2013b)
Positive
High P (High N for some)
Low N (DIN, DON) (only
applies to N2 fixers)
Low N:P Ratios
Low turbulence
Low water flushing-Long
water residence time
High (adequate) light
Warm temperatures
High dissolved organic
matter
Sufficient Fe (+ trace
metals)
Low grazing rates
w
CD
¦4—11
CO
tr
Cyanos
•jj¦
VP
w
CD
CO
cc
Diversity
Modulating factors
Strong biogeochemical gradients (e.g.
persistent stratification, stable benthos)
Heterogeneous and diverse habitats (e.g.
reefs, seagrasses, marshes, sediments,
aggregates)
Selective grazing
"Toxin" production??
Negative
High DIN/total N (only
applies to N2 fixers)
Low P (DIP)
High N:P ratios
High turbulence & vertical
mixing
High water flushing-Short
water residence time
Low light (for most taxa)
Cool temperatures
Low dissolved organic
matter
Low Fe (+ trace metals)
High grazing rates
Viruses (cyanophages)
Predatory bacteria
2.3
Environmental Fate of Anatoxin-a
2.3.1
Hydrolysis
Studies have shown that in the absence of sunlight, the half-life of anatoxin-a can range
from several days to several months (Stevens and Krieger, 1991a; Smith and Sutton, 1993; Yang,
2007). Alkaline conditions accelerate anatoxin-a breakdown (see below) (Stevens and Krieger,
1991a). Matsunaga et al. (1989) have reported that anatoxin-a can be relatively stable under
neutral and acidic conditions.
2.3.2
Photolysis
Anatoxin-a differs from other cyanotoxins (like microcystins) in that it undergoes rapid
photochemical degradation in sunlight even in the absence of cell pigments (WHO, 1999).
Stevens and Krieger (1991a) found that the degradation of anatoxin-a is dependent on the light
intensity and/or pH, with higher pH favoring degradation reactions. Under simulated natural
conditions, photolysis is an important degradation pathway for anatoxin-a, with a half-life of 1 to
2 hours at pH ranges from 8 to 9. Yang (2007) reported a first-order half-life for anatoxin-a of 4-
10 hours in natural light. However, laboratory experiments using reservoir water with sediment
microbial populations found an anatoxin-a half-life of five days (Smith and Sutton, 1993). In the
Health Effects Support Document for Anatoxin-a - June 2015
10
-------
same study, the authors found anatoxin-a for at least 21 days at pH 4, and detectable levels after
14 days at pH 8 and 10.
2.3.3 Metabolism
Anatoxin-a can be readily degraded by bacteria associated with cyanobacterial filaments;
however, there is less information available for anatoxin-a than for other cyanotoxins (i.e.
microcystins).
2.3.4 Transport
Anatoxin-a is weakly sorbed to sandy sediments. The strongest sorption is to clay-rich
and organic-rich sediment. Researchers found that sorption follows a non-linear Langmuir
model, such that it is linear at lower concentrations with sorption decreasing at higher
concentrations. Organic matter promotes sorption of the anatoxin-a molecule due to the
availability of negatively charged sites (Klitzke et al., 2011).
2.4 Summary
Anatoxin-a is produced by a variety of cyanobacteria. Factors such as nutrient levels, pH,
light intensity and temperature influence the growth of these cyanobacteria and could encourage
toxin production. The half-life of anatoxin-a in the absence of sunlight ranges from several days
to several months. However, in sunlight anatoxin-a undergoes rapid photochemical degradation
even in the absence of cell pigments. Degradation is dependent on pH, with higher pH favoring
more rapid degradation reactions. The half-life of anatoxin-a in sunlight is 1 to 2 hours at a pH of
8 to 9. Anatoxin-a can be degraded by bacteria associated with cyanobacterial filaments. It is
weakly sorbed to sandy sediment, but has strong sorption to clay- and organic-rich sediment.
Organic matter promotes sorption of the anatoxin-a molecule due to the availability of negatively
charged sites.
Health Effects Support Document for Anatoxin-a - June 2015
11
-------
3.0 CYANOTOXIN OCCURRENCE AND EXPOSURE IN WATER
The presence of detectable concentrations of cyanotoxins in the environment is closely
associated with blooms of cyanobacteria. Cyanobacteria flourish in various natural environments
including salty, brackish or fresh water, cold and hot springs, and in environments where no
other microalgae can exist, including desert sand, volcanic ash and rocks (Jaag, 1945; Dor and
Danin, 1996). Cyanobacteria also form symbiotic associations with aquatic animals and plants,
and cyanotoxins are known to bioaccumulate in common aquatic vertebrates and invertebrates
(Ettoumi et al. 2011).
Currently, there is no national database recording freshwater harmful algal bloom (HAB)
events. Instead, state and local governments document HAB occurrences in various ways
depending on the monitoring methods used and the availability of laboratories capable of
conducting algal toxin analyses.
Human exposure to cyanotoxins, including anatoxin-a, may occur by direct ingestion of
toxin-contaminated water or food, and by inhalation and dermal contact during bathing,
showering or during recreational activities in water bodies contaminated with the toxins.
Anatoxin-a can be dissolved in drinking water either by the breakdown of a cyanobacterial
bloom or by cell lysis. Exposure through drinking water can occur if there are toxins in the water
source and the existing water treatment technologies were not designed for removal of
cyanotoxins. Because children consume more water per unit body weight than do adults, children
potentially may receive a higher dose than adults. Exposures are usually not chronic; however,
they can be repeated in regions where cyanobacterial blooms are more extensive or persistent. As
described above, anatoxin-a is not highly persistent; thus exposure to anatoxin-a from ambient
surface waters is more likely to be acute or subacute. People, particularly children, recreating
close to lakes and beach shores also can be at potential risk from exposure to nearshore blooms.
Livestock and pets potentially can be exposed to higher concentrations of cyanobacterial
toxins than humans because they are more likely to consume scum and mats while drinking
cyanobacteria-contaminated water (Backer et al., 2013). Dogs are particularly at risk as they may
lick cyanobacteria from their fur after swimming in a water body with an ongoing bloom.
3.1 General Occurrence of Cyanobacteria in Water
Species of cyanobacteria are predominantly found in eutrophic (nutrient-rich) water
bodies in freshwater and marine environments (ILS, 2000), including salt marshes. Most marine
cyanobacteria of known public health concern grow along the shore as benthic vegetation
between the low- and high-tide water marks. The marine planktonic forms have a global
distribution. They also can be found in hot springs (Castenholz, 1973; Mohamed, 2008),
mountain streams (Kann, 1988), Arctic and Antarctic lakes (Skulberg, 1996) and in snow and ice
(Laamanen, 1996).
3.2 Anatoxin-a Occurrence in Surface Water
Health Effects Support Document for Anatoxin-a - June 2015
12
-------
Gas vacuoles of A. ovalisporum and C. raciborskii act to regulate the position of the
cyanobacteria in the water column. These species of cyanobacteria do not form a floating scum,
but concentrate (with densities up to 100,000 cells/mL) several meters below the surface.
Because the cells remain suspended in the water column, potentially toxin-producing blooms of
these cyanobacteria may not be readily observable.
Reported concentrations of anatoxin-a are limited and vary widely depending on the
water body sampled and the analytical method used. Anatoxin-a has been found in surface
waters around the world including in the U.S. (Carmichael et al., 1975; Carmichael et al., 2001).
Concentrations of anatoxin-a in surface freshwater cyanobacterial blooms or surface freshwater
samples reported worldwide from 1985 to 1996 ranged from 0.4 to 4,400 |ig/g dry-weight.
Reported water-volume concentrations of extracellular and intracellular anatoxin-a ranged from
0.02 to 0.36 |ig/L (WHO, 1999).
Monitoring and analysis of U.S. surface water described below has shown concentrations
of anatoxin-a ranging from below the detection limit (0.05 |ig/L) to 1,929 |ig/L.
In 2006, the U.S. Geological Survey (USGS) conducted a targeted study of cyanotoxins
in Midwestern waters (Loftin et. al., 2008; Graham et al., 2010). Twenty-three samples were
collected from lakes in the Midwest (MN, IA, MO, KS) over a 1-week period in August 2006
and were analyzed by liquid chromatography-tandem mass spectrometry (LC-MS/MS).
Anatoxin-a was detected in about a third of the samples at concentrations of 0.05 to 10 |ig/L.
Yang (2007) analyzed anatoxin-a using high performance liquid chromatography with
fluorescence detection (HPLC/FD) and reported periodic detections of anatoxin-a at
concentrations above 0.1 [j,g/L in samples collected from western Lake Erie, along the southern
shoreline of Lake Ontario and in Lake Champlain. Higher concentrations exceeding 1 [j.g/L of
anatoxin-a were reported in samples collected from Onondaga Lake and Lake Agawam, smaller
inland lakes in New York State (Yang, 2007).
Hedman et al. (2008) sampled surface waters in Wisconsin using LC-MS/MS and
detected anatoxin-a in 4 of 74 samples with concentrations ranging from 0.68 to 1,750 |ig/L.
Ohio EPA (2010) reported anatoxin-a concentrations ranging from below the detection
limit to 15 |.ig/L in Grand Lake St. Mary's, Ohio using enzyme-linked immunosorbent assay
(EL1SA).
The Washington State Department of Ecology used LC-MS/MS to test for anatoxin-a and
other toxins in Washington's lakes, ponds and streams from 2009 to 2011 (WSDE, 2012). In
2009, of the 32 lakes tested for anatoxin-a, 44% of lakes had detectable concentrations ranging
from 0.05 to 144 |ig/L. In 16% of the lakes tested, the concentration of anatoxin-a was above the
recreational guidance level established by the state of 1 (J,g/L. In 2010, 41 lakes were tested for
anatoxin-a; 24% of lakes had anatoxin-a concentrations ranging from 0.05 to 538 |ig/L. In 12%
of the lakes sampled, the concentration of anatoxin-a was above the recreational guidance level
of 1 |ig/L. In samples taken in 2011 from 46 lakes, anatoxin-a concentrations varied from 0.05 to
Health Effects Support Document for Anatoxin-a - June 2015
13
-------
1,929 jj,g/L in 57% of the lakes tested. In 13% of the lakes sampled in 2011, levels were above
the state recreational guideline of 1 (J,g/L.
Al-Sammak et al. (2014) detected anatoxin-a in samples collected from 12 reservoirs in
Nebraska between 2009 and 2010. Samples were analyzed using HPLC/FD for the preliminary
analysis of all extracts, and LC-MS/MS was used for confirmation. Anatoxin-a was detected in
31 of the 67 samples at concentrations ranging from 0.05 [j.g/L (detection limit) to 35 (J,g/L.
3.3 Anatoxin-a Occurrence in Drinking Water
Data on the presence of cyanotoxins, including anatoxin-a, in drinking water and finished
drinking water are scarce and generally not published. In drinking water, the occurrence of
cyanotoxins depends on their level in the raw source water and the effectiveness of the drinking
water treatment. Currently, there is no national regulatory program in place to monitor for the
occurrence of cyanotoxins in drinking water in the U.S. In 2008, anatoxin-a was detected in three
samples of finished water in Florida ranging from below the detection limit to 8.46 |ig/L (Burns,
2008). Methods employed to characterized algal toxins included ELISA, protein phosphatase
inhibition assay (PPIA), HPLC, and LC/MS/MS (no detection limits were reported).
3.4 Summary
Anatoxin-a -producing cyanobacteria occur in freshwater systems around the world and
in the U.S. No national database recording freshwater anatoxin-a is available. The available data
for the occurrence of anatoxin-a in surface waters and drinking water is by published literature
and reports such as the USGS. A survey done by USGS in 2006 of 23 lakes in the Midwestern
U.S., found that anatoxin-a was detected in about a third of the samples at concentrations from
0.05 to 10 |ig/L. Data on the presence of anatoxin-a, in drinking water and finished drinking
water are scarce and generally not published. In Washington State, samples taken in 2011 from
46 lakes had anatoxin-a concentrations from 0.05 to 1,929 (J,g/L. A survey conducted in 1999 in
Florida, found that anatoxin-a occurred in three finished water samples ranging from below the
detection limit to 8.46 |ig/L
Exposure to anatoxin-a from contaminated drinking water sources may occur mostly via
oral exposure (e.g. ingestion of contaminated drinking), dermal exposure (contact of exposed
parts of the body with water containing toxins); and inhalation exposure. Exposure to anatoxin-a
during recreational activities may be due through direct contact, inhalation and/or ingestion.
Exposures are usually not chronic with the exception of regions with extensive and persistent
cyanobacterial blooms. Since anatoxin-a is not highly persistent, exposure from ambient surface
waters is more likely to be acute or subacute. Since children consume more water per unit body
weight than do adults, children may potentially receive a higher dose. Pets, livestock and wildlife
are also potentially exposed to cylindrospermopsin when consuming scum and mats, and
drinking cyanobacteria-contaminated water.
Health Effects Support Document for Anatoxin-a - June 2015
14
-------
4.0 OCCURRENCE IN MEDIA OTHER THAN WATER
4.1 Occurrence in Soil and Edible Plants
Cyanobacteria are highly adaptable and have been found to colonize infertile substrates,
such as volcanic ash and desert sand (Jaag, 1945; Dor and Danin, 1996; Metcalf et al., 2012).
They also have been found in soil, at the surface or several centimeters below the surface, where
they play a functional role in nutrient cycling. Cyanobacteria are known to survive on rocks or
tree trunks, and in snow and ice (Adhikary, 1996). They have been reported in deeper soil layers
likely transported by percolating water or burrowing animals. Some freshwater species are
halotolerant (salt tolerant) and have been found in saline environments such as salt works or salt
marshes (WHO, 1999). Cyanobacterial cells can bioaccumulate in zooplankton (Watanabe et al.,
1992). As a result of higher trophic level grazing, the damaged or residual cyanobacterial cells
may settle out of the water column and accumulate in sediment where breakdown by sediment
bacteria and protozoa can release their toxins (Watanabe et al., 1992).
Al-Sammak et al. (2014) detected anatoxin-a in aquatic plant samples collected from 12
reservoirs sampled in Nebraska from 2009 to 2010. Both bound and free anatoxin-a were
measured in 18 of 48 plant samples analyzed. The bound anatoxin-a concentrations ranged from
1.47 to 8.01 |ig/g. Concentrations of free anatoxin-a ranged from 0.26 to 0.61 |ig/g. Plant
detections generally co-occurred with detections in water and, in the water samples, bound
anatoxin-a concentrations were generally higher than free concentrations.
4.2 Occurrence in Fish and Shellfish
Cyanotoxins can bioaccumulate in common aquatic vertebrates and invertebrates,
including fish, snails (Carbis et al., 1997; Beattie et al., 1998; Berry et al., 2012) and mussels
(Eriksson et al., 1989; Falconer and Yeung, 1992; Prepas et al., 1997; Watanabe et al., 1997;
Funari and Testai, 2008). Bioconcentration in fish has been reported (Osswald et al., 2011) with
bioconcentration factors ranging from 30 to 47 based on fresh weight. Human exposure to
cyanotoxins may occur if fish are consumed from reservoirs with existing blooms of toxin-
producing cyanobacteria (Magalhaes et al., 2001).
The health risk from consumption depends on the bioaccumulation of toxins in edible
fish tissue. Because fish are generally more tolerant of cyanobacterial toxins than mammals, they
tend to accumulate them over time (ILS, 2000). Very limited information was available
regarding anatoxin-a accumulation in fish. Osswald et al. (2007) exposed juvenile common carp,
Cyprinus carpio, to freeze-dried cells of Anabaena sp. at a cell density of 105 or 107 cells/mL for
four days. Toxin content measured in extracts from whole fish was 0.005 and 0.073 |ig/g fresh
weight, respectively. In a study by Al-Sammak et al. (2014), anatoxin-a was not detected in any
fish samples collected from 248 fish, including bottom feeding fish such as carp and catfish,
from 12 Nebraska lakes.
Health Effects Support Document for Anatoxin-a - June 2015
15
-------
4.3
Occurrence in Dietary Supplements
Extracts from Arthrospira (Spirulina spp.) and Aphanizomenon flos-aquae (AFA) have
been used as dietary bluegreen algae supplements (BGAS) (Funari and Testai, 2008). These
supplements are reported to have beneficial health effects including supporting weight loss, and
increasing alertness, energy and mood elevation for people suffering from depression (Jensen et
al., 2001). In children, they have been used as an alternative, natural therapy to treat attention
deficit hyperactivity disorder (ADHD). Heussner et al. (2012) did not detect anatoxin-a in 18
commercially available BGAS analyzed for the presence of toxins. However, Rellan et al. (2009)
reported that three of 39 samples (7.7%) of BGAS contained anatoxin-a at concentrations
ranging from 2.50 to 33 jug/g.
4.4 Summary
Anatoxin-a could be detected in aquatic animals and edible plants. Very limited
information was available on anatoxin-a accumulation in fish. No cases of toxicity in humans
following ingestion of fish or shellfish exposed to cyanotoxins have been documented.
Anatoxin-a have been found in algal supplements ranging from 2.5 to 33 jug/g. Exposure
for the general population is mostly through the ingestion of drinking water and incidental
ingestion when recreating in a contaminated water source.
16
Health Effects Support Document for Anatoxin-a - June 2015
-------
5.0 TOXICOKINETICS
Data on the toxicokinetics of anatoxin-a are negligible. Absorption and distribution are
demonstrated only by the rapid appearance of neurotoxicity and the systemic effects observed
after exposures in repeat dose studies.
5.1 Absorption
No information regarding the absorption of anatoxin-a in humans or animals was
identified. However, acute oral toxicity studies in animals demonstrate that it can be absorbed
rapidly by the gastrointestinal tract. Symptoms of clinical neurotoxicity such as muscular
twitching, loss of coordination and death from respiratory paralysis occur within minutes of
exposures (Stevens and Krieger, 1991a; Fitzgeorge et al., 1994).
5.2 Distribution
The rapid appearance of symptoms following exposure is consistent with rapid uptake
from the gastrointestinal tract and serum distribution to the liver, brain and central nervous
system. In a study by Fitzgeorge et al. (1994), deaths in mice occurred by respiratory paralysis
within 2 minutes of gavage administration of doses greater than 5 mg/kg. In bioassay studies,
Stevens and Krieger (1991a) found that lethal doses (concentrations not reported) manifested the
same signs of respiratory paralysis as control solutions of anatoxin-a, and that the breakdown
products of anatoxin-a are less toxic than the parent compound.
5.3 Metabolism
No information on the metabolism of anatoxin-a was identified.
5.4 Excretion
No information regarding the excretion of anatoxin-a was identified.
5.5 Pharmacokinetic Considerations
No data on half-life or other quantitative pharmacokinetic parameters for anatoxin-a were
identified. The interactions with the nicotinergic acetylcholine receptor are known to be
enanteromerically specific [(+) isomer only]. The (-) isomer also has toxic properties based on
lethality studies. However, the (-) isomer lacks the direct neurotoxicity of the (+) isomer.
Health Effects Support Document for Anatoxin-a - June 2015
17
-------
6.0 HAZARD IDENTIFICATION
6.1 Case Reports and Epidemiology Studies
Information on epidemiology studies or confirmed case reports of human poisoning from
exposure to anatoxin-a are not available.
Non-lethal human poisonings, usually manifested as acute gastrointestinal disorders such
as nausea, vomiting and diarrhea, have been related to ingesting water with unspecified species
of Microcystis and Anabaena (producers of anatoxin-a) as later detected in the victims' feces
(Schwimmer and Schwimmer, 1968). Allergic reactions (e.g., skin papulo-vesicular eruptions)
have been related to swimming in water with a bloom of Anabaena (Schwimmer and
Schwimmer, 1968). However, anatoxin-a detections were not reported.
Anatoxin-a has been associated with poisonings and deaths of livestock, dogs and ducks
after exposure to water contaminated with cyanotoxins (Carmichael and Gorham, 1978; Edwards
et al., 1992; Gunn et al., 1992; Puschner et al., 2008; Stewart et al., 2008). Quantitative exposure
data were not reported but clinical signs were mostly neurologic and deaths due to respiratory
paralysis, characteristic adverse effects of anatoxin-a. In the U.S., 368 cases of cyanotoxin
poisonings associated with dogs were identified in a review done by the Centers for Disease
Control (CDC) from the 1920s to 2012 (Backer et al., 2013). A retrospective review of
veterinary biopsy and necropsy case files between 1984 and 2012 found that of the 71 cases of
dogs deaths, 45 (4%) were either suspected or confirmed cyanotoxins poisoning. Two dogs (3%)
were confirmed with anatoxin-a poisoning. Both dogs died within 20 to 30 minutes of onset of
illness after exposure to cyanobacteria in a backyard pond. Anatoxin-a was identified in the
kidney by biochemical testing (Backer et al., 2013).
6.2 Animal Studies
6.2.1 Acute Toxicity
6.2.1.1 Oral Exposure
Stevens and Krieger (1991b) used a single dose gavage in adult male Swiss Webster ND-
4 mice to determine an LD50 of 16.2 mg/kg (Confidence Interval [CI] of 95%: 15.4-17.0) for
synthetic (+)-anatoxin-a hydrochloride ( >98% pure commercial product), which is equivalent to
13.3 mg anatoxin-a/kg (95% CI: 12.8-14.1). When using a lysate solution of lyophilized A.flos-
aquae (NRC-44-1) cells, an LD50 value of 6.7 mg/anatoxin-a kg (95% CI: 6.3-7.1) was
determined. The LD50 values were determined using the method of moving averages for four
doses with six animals per dose (Stevens and Krieger, 1991b).
A single dose gavage study in newly weaned CBA/BalbC mice of unspecified sex
determined an LD50 of >5 mg/kg for anatoxin-a; the study authors used a "suitably purified" but
an unspecified form of commercial product (Fitzgeorge et al., 1994). Deaths due to
neurotoxicity, expressed as muscular twitching, loss of coordination and death by respiratory
paralysis, occurred within 2 minutes of administration (Fitzgeorge et al., 1994).
Health Effects Support Document for Anatoxin-a - June 2015
18
-------
A 5-day gavage, range-finding study was conducted to determine the maximum tolerated
dose for use in a 28-day study (Section 6.2.2) (Fawell and James, 1994; Fawell et al., 1999).
Doses of 1.5, 3, 7.5 or 15 mg/kg-day (equivalent to 1.2, 2.5, 6.2 or 12.3 mg anatoxin-a/kg-day)
using aqueous (+)-anatoxin-a hydrochloride (commercial product, purity not reported) were
administered to 2 male and 2 female Crl:CD-l(ICR)BR mice groups (no control group included).
After 24 hours of administering the lower dose (1.2 mg/kg-day), the 6.2 and 12.3 mg/kg-day
dosing started. After 5 days, the 2.5 mg/kg-day (intermediate level) dosing was administered.
Evaluation of clinical signs, food consumption and body weight were done and the surviving
animals were necropsied. During the first 4 days, all mice in the high-dose group died (within 5
minutes of dosing), and one female mouse from the 6.2 mg/kg-day group died. These deaths
happened within 5 minutes of dosing. The male mice in the 6.2 mg/kg-day dose group were
hyperactive following the third dose. The rest of the surviving animals in this group (6.2 mg/kg-
day) did not express any abnormal clinical signs and no other signs of neurotoxicity were
reported. The 6.2 mg/kg-day dose was identified as the Frank Effect Level (FEL) based on the
death of one of the two female mice. The maximum tolerated dose was established as 3
mg/kg/day anatoxin-a hydrochloride (2.5 mg/kg/day anatoxin-a).
6.2.1.2 Other Exposure Routes
A single dose intraperitoneal (i.p.) study in mice identified an LD50 of 0.25 mg/kg (95%
CI: 0.24-0.28) for (+)-anatoxin-a hydrochloride (commercial product, >98% pure) equivalent to
0.21 mg anatoxin-a/kg (Stevens and Krieger, 1991b). In another i.p. study, Fitzgeorge et al.,
(1994) determined an LD50 of 0.375 mg/kg for commercial anatoxin-a (form and purity not
reported).
Single i.p. injections of (+)-, racemic or (-)-anatoxin-a hydrochloride (all >95% pure)
were administered in male BalbC mice (Valentine et al., 1991). After observing for 30 minutes,
LD50 values were determined as 386 (J,g/kg (95% CI: 365-408) for (+)-anatoxin-a hydrochloride
equivalent to 0.32 mg anatoxin-a/kg and 913 (J,g/kg (95% CI: 846-985) for racemic anatoxin-a
hydrochloride equivalent to 0.76 mg anatoxin-a/kg. According to the authors, this two-fold
potency difference is consistent with mechanistic data indicating that (+)-anatoxin-a is the
biologically active enantiomer.
An i.p. 2-day study in 18 female CD-I mice was performed to determine a maximum
dose to evaluate neurodevelopmental toxicity (Section 6.2.3) (Rogers et al., 2005). Dosages of
anatoxin-a (commercial product, >90% purity) in distilled water were 10, 100, 200, 250, 300 and
400 (J,g/kg (0.008, 0.08, 0.17, 0.21, 0.25 and 0.33 mg anatoxin-a/kg-day). Group sizes ranged
from 1 in the 400 (J,g/kg dose group to 6 in the 100 (J,g/kg group (Personal communication). After
5 to 6 minutes of administering the higher dose, mice expressed decreased motor activity, altered
gait, difficulty breathing and convulsions. Anatoxin-a was 100% lethal at the 400 (J,g/kg after 10
minutes. Mice receiving 100 or 200 |ig/kg survived and received a second dose of racemic
anatoxin-a the following day. All mice survived after the second dose. Clinical signs of toxicity
after 10 minutes of administering the lower doses included decreased activity level, altered gait
and breathing irregularities. At the lower doses, mice did not have convulsions and recovery was
observed by 15 to 20 minutes after treatment (Rogers et al., 2005).
Health Effects Support Document for Anatoxin-a - June 2015
19
-------
6.2.2
Short Term Studies
In the 28-day study, four groups of 10 male and 10 female mice were dosed by gavage
once a day for 28 days with 0 (vehicle control), 0.12, 0.6 or 3 mg/kg-day (corresponding to
0.098, 0.49 and 2.46 mg anatoxin-a/kg-day) (Fawell and James, 1994; Fawell et al., 1999).
Histological and blood analysis examinations were performed in the control and dose groups,
and microscopic examinations were done to all tissues. During the study, three deaths were
reported within 2.5 hours of dosing: one from each of the high dose groups (a male from the 0.49
mg anatoxin-a/kg-day group and a female from the 2.46 mg anatoxin-a/kg-day group), but no
cause for these deaths was determined. The authors did not demonstrate any clear clinical signs
of general toxicity, such as changes in body weight, altered food consumption or unusual
necropsy findings. The third death was not related to treatment. The animal was sacrificed after
showing signs of having been attacked by its cage mates.
The only adverse clinical signs observed among the survivors, although not considered
toxicologically significant, were a significant increase in mean cell hemoglobin concentration in
males at >0.1 mg/kg-day and in females at >0.5 mg/kg-day, and an increase in serum sodium in
females at >0.5 mg/kg-day. No significant changes were observed in serum levels for liver
enzymes, albumin, BUN or sodium. The study authors determined a NOAEL (No Observed
Adverse Effect Level) of 0.1 mg/kg-day (0.098 mg anatoxin-a hydrochloride/kg-day) based on
the deaths in the higher dose groups (Fawell and James, 1994; Fawell et al., 1999).
6.2.3 Subchronic Studies
6.2.3.1 Oral Exposure
Anatoxin-a extracted from the culture media of A. jlos-aquae (NRC-44-1) cells and
partially purified by high pressure liquid chromatography (HPLC) in a 30% perchloric acid/70%
methanol solvent (purity not quantified) was administered in drinking water to groups of 20
female Sprague-Dawley rats (Astrachan and Archer, 1981; Astrachan et al., 1980). Doses of 0,
0.51, or 5.1 mg/kg were administered for 7 weeks with an estimated daily intake of anatoxin-a in
the low dose group of 0.05 mg/kg-day and 0.5 mg/kg-day in the high dose group. Daily intake
was estimated assuming that the test rats consumed 0.1 mL/g body weight per day (based on a
preliminary water consumption study). The authors evaluated food consumption, body weight,
red and total white blood cell counts, and serum enzyme activities throughout the study. At the
end of the study, the authors evaluated hepatic mixed function oxidase activity (aldrin
epoxidation in vitro), organ weights (liver, kidneys and spleen), and gross pathology and
histology (liver, kidneys, spleen, adrenals, heart, lungs and brain).
No clinical signs attributed to treatment were observed and a NOAEL of 0.5 mg/kg-day
was identified by the authors. Graphic data were reported for the hematological effects and liver
enzymes (Astrachan and Archer, 1981). There were no apparent differences in the red blood cell
(RBC) counts (mm3x 10"6), alkaline phosphatase (ALP), and aspartate aminotransferase (AST).
There was a dose- and duration-related increase in white cell counts (mm3 x 10"3). White cell
counts for the low dose group reached normal levels by week 3, but not until week 7 for the high
20
Health Effects Support Document for Anatoxin-a - June 2015
-------
dose group. Organ weights were similar and no gross or histological tissue abnormalities were
observed. The graphic presentation of the hematology data does not support determination of
statistical significance for the effects on the white cell counts. They remained about 30 to 50%
higher (estimate from the figure in the report) than the controls over the first 5 weeks of the
study. The high dose can be considered as a LOAEL (Lowest Observed Adverse Effect Level)
for the white blood cell effects. At one week the elevation of the white cell count was
approximately equivalent to that for the high dose, but at 3 weeks was comparable to controls.
There are insufficient data from other studies to determine whether the white cell effects should
be regarded as toxicologically adverse.
6.2.3.2 Other Exposure Routes
Neurotoxicity
In a neurodevelopmental study, racemic (+/-)-anatoxin-a hydrochloride (commercial
product, >90% purity) was administered to groups of 8 to 11 time-pregnant CD-I mice (Rogers
et al., 2005). Doses of 0 (control), 125 or 200 [j,g/kg-day equivalent to 0, 0.09 or 0.15 mg
anatoxin-a/kg-day on gestation days (GD) 8-12 or 13-17 were administered via i.p. injection in
distilled water. After all mice gave birth, body weight and viability of the pups were determined
on postnatal days (PND) 1 and 6. Immediately after treatment, toxicity in the pregnant mice was
observed at 0.15 mg/kg-day expressed as decreased motor activity. PND evaluation did not find
effects on pup viability (number of live pups) on PND 1 or 6 in mice treated on GD 8-12 or 13-
17. No effects were observed on pup body weight on PND 1 or 6 in mice treated on GD 8-12
either. However, a statistically significant dose-related trend for reduced body weight was
observed in pups treated on GD 13-17 on PND 1 (p<0.05) only. On PND 1, body weights in the
pups exposed on GD 13-17 showed a trend (7.1 and 8.7% less than controls) at the two higher
doses (0.09 and 0.15 mg/kg-day, respectively) but the authors' reported differences from controls
were not significant. The authors attributed the trend in reduced pup body weight to random
variability in litter size (GD 13-17 controls were noticeably smaller than the treated groups;
p=0.09). A difference in litter size would have an impact in both birth weight and growth on
PND 1 and 6 since pups in smaller litters are larger at birth (McCarthy, 1967) and will grow
more rapidly postnatally (Rogers et al., 2003). A NOAEL for the racemic mixture was identified
as 0.09 mg/kg-day for the dams based on decreased post treatment motor activity and a LOAEL
of 0.15 mg/kg-day (Rodgers et al., 2005).
Righting reflex, negative geotaxis and hanging grip time were evaluated only on PND 6,
12 and/or 20 in pups from dams exposed on GD 13-17 (Rogers et al., 2005). Righting reflex
(measurement of the time a pup takes to turn from his back to an upright position) was tested on
PND 6 and 12; negative geotaxis (time to rotate on an inclined screen facing downhill to facing
up the incline) was tested on PND 6, 12 and 20; and hanging grip time (time when a pup let go
after the pup grasped a bar with their front feet to hang) was tested on PND 12 and 20. The
reason for testing only the pups exposed on the GD 13-17 was because this gestational interval
follows the onset of neurogenesis in the mouse brain (Rice and Barone, 2000). The litters from
the exposed dams were normalized to eight pups (including four male and four female pups) on
PND 6, and on each test day a randomly selected male and female pup from each litter was
evaluated.
Health Effects Support Document for Anatoxin-a - June 2015
21
-------
Based on the results from the testing (righting reflex, negative geotaxis and hanging grip
time), postnatal neurotoxicity was not observed (Rogers et al., 2005). Results showed no
statistically significant differences between exposed and control groups and no dose-related
differences. However, a non-statistically significant (p<0.086) dose-related trend was observed
for slower righting reflex in males in the righting reflex test on PND 6. A significant (p value not
reported) sex-difference was observed in terms of a slower reflex in females than in males in all
treatment groups on PND 6. No sex-difference or treatment differences in righting reflex were
observed on PND 12.
Turning times did not decrease as expected from PND 6 to 20 in the negative geotaxis
test (Rogers et al., 2005). In addition, control and treated pups fell off the screen before turning.
Data from those mice that stayed on the inclined screen showed no significant differences across
treatment groups in both the number of fallen mice and the average turning times. Also, no
treatment-related differences in hanging grip time on either test day were observed. In the
hanging grip time test, the authors found that the hang time in females increased significantly
from PND 12 to 20, but males did not show an expected increase in hanging grip time. The
investigators indicated that random variability in the tested population may be the reason for the
sex-difference (Rogers et al., 2005).
To evaluate the effect of prenatal exposure to anatoxin-a on the motor activity of adult
mice and their responses to nicotine challenge, mouse pups already exposed to 0, 0.09 or 0.15
mg anatoxin-a/kg-day on GD 8-12 or 13-17 in the Rogers et al. (2005) study were tested as
adults by MacPhail et al. (2005). Motor activity was measured on approximately 8-month-old
offspring during 30-minute sessions using a photocell device. Doses of 0, 0.1, 0.3, 1.0 or 3.0
mg/kg nicotine in saline were administered subcutaneously to groups of 12 male and 12 female
mice approximately 5 minutes before testing motor activity. These mice were assigned to the
nicotine dose groups regardless of the gestational period during which they received anatoxin-a.
A dose-related decrease was observed in both horizontal and vertical activity. In both sexes, 0.65
mg/kg nicotine was identified as the effective dose in 50% (ED50) of the animals.
Adult offspring from mice exposed to the racemic anatoxin-a on GD 13-17 were given
nicotine at the ED50 or saline vehicle about 5 minutes before testing the motor activity (MacPhail
et al., 2005). Both treatments (nicotine ED50 and saline vehicle) were separated by 1 week. The
group sizes were composed of 10 mice per gender for each dose with the exception of the high-
dose anatoxin-a female group, which consisted of 9 mice. Although no quantitative data were
provided, graphical displays show no differences in horizontal or vertical motor activity between
the anatoxin-a-exposed mice and the controls. No dose-response for either male or female mice
to the nicotine challenge was observed (MacPhail et al., 2005).
The Irwin Screen was used to evaluate neurobehavioral effects of anatoxin-a in mice
(Fawell and James, 1994; Fawell et al., 1999). The Irwin Screen is a systematic observational
procedure used to assess Central Nervous System (CNS) effects such as motor activity,
sensory/motor reflex responses, coordination and behavioral changes. Intravenous injections of
(+)-anatoxin-a hydrochloride (commercial product, purity not reported) were administered in
doses of 10, 30 or 100 (J,g/kg (equivalent to 8, 25 or 82 jag anatoxin-a/kg) to 6 mice with a
Health Effects Support Document for Anatoxin-a - June 2015
22
-------
positive control to evaluate cholinergic effects of 300 |ig/kg of nicotine. After dosing, the mice
were observed at 15 and 30 minutes, and 1, 2 and 4 hours (Fawell and James, 1994; Fawell et al.,
1999). Within 1 minute of dosing, all the mice (6 in total) in the high dose group (82 jag
anatoxin-a/kg) died exhibiting symptoms of cholinergic stimulation and CNS effects such as
increased respiration, salivation, micturition (urination), hyperactivity and Straub tail. Two
animals in the 25 jag anatoxin-a/kg dose group died and those that survived showed increased
salivation, respiration and hyperactivity. No effects were observed in the low dose group (8
[j,g/kg anatoxin-a/kg).
A rota-rod test to evaluate sensorimotor coordination based on the ability of the animal to
remain on a rotating rod also was performed on CD-I strain mice (Fawell and James, 1994;
Fawell et al., 1999). Seven groups of male mice were dosed with 0, 30, 50 or 60 mg/kg anatoxin-
a as the hydrochloride salt (equivalent to 25, 41 or 49 mg/kg anatoxin-a), and 300, 500 or 5,000
mg/kg of nicotine (standard) and with phosphate buffered saline (vehicle control). Fifteen
minutes after dosing, mice were placed onto the rota-rod for a 3-minute period and the authors
recorded the time taken to fall off. Within 1 minute of dosing, only the highest doses caused
clinical signs of neurotoxicity and death. Death was observed in 3 of 3, 2 of 6 and 1 of 6 of the
mice dosed with 49, 41 and 25 mg/kg anatoxin-a, respectively, and in 4 of 5 animals dosed with
the highest nicotine dose (5,000 mg/kg). Prior to death, mice showed symptoms of CNS effects
and cholinergic stimulation. No exposure-related effects were observed in the rest of the dosed
animals with the exception of 2 of 6 animals dosed with 500 mg/kg of nicotine that showed
elevated respiration rates for 1 minute (Fawell and James, 1994; Fawell et al., 1999).
The effects of anatoxin-a on operant performance was evaluated in adult male Long
Evans rats (MacPhail et al., 2007). Groups of 8 rats trained to respond under a multiple variable-
ratio variable-interval schedule of food reinforcement were given (+)-anatoxin-a fumarate in
subcutaneous injections at 0 (control), 0.05, 0.075, 0.1, 0.15 or 0.2 mg/kg doses equivalent to 0,
0.03, 0.045, 0.06, 0.09 and 0.12 mg anatoxin-a/kg, respectively) weekly for four weeks. Dose-
related decreases in performance were observed at 0.06, 0.09 and 0.12 mg/kg doses. At the two
highest doses, mild tremors were observed. Over subsequent weeks, diminished effects were
observed indicative of tolerance development. In an operant conditioning procedure, those rats
that were administered a single dose of 0.1 mg/kg (+)-anatoxin-a fumarate (0.06 mg anatoxin-
a/kg) showed decreased locomotor activity and a partial nicotine-like discriminative stimulus
effect in animals trained to discriminate nicotine from saline (MacPhail et al., 2007). Anatoxin-a
also decreased the response and reinforcement rates in rats in multiple-schedule operant
performance tests (Jarema and MacPhail, 2003). However, upon repeated administration,
substantial tolerance was developed.
Reproductive/Developmental Toxicity
Fawell et al. (1999) reported the results of a developmental toxicity screening study of
anatoxin-a in timed-pregnant female CD-I mice. Gavage dosing occurred with either vehicle or
2.5 mg/kg/day anatoxin-a as the hydrochloride salt on GD 6-15. Maternal body weights and
clinical signs were recorded. On GD 18, the mice were sacrificed. Live and dead fetuses were
counted, weighed, sexed and observed for external abnormalities. The raw data were not
provided. The authors reported a lack of maternal toxicity. There was no effect of treatment on
23
Health Effects Support Document for Anatoxin-a - June 2015
-------
mean fetal weight, sex ratio or post implantation losses. There were also no treatment-related
major fetal abnormalities.
In a reproductive study, male mice were administered doses of 0 (control), 0.05, 0.1 and
0.15 mg/kg-day anatoxin-a for seven consecutive days (Yavasoglu et al., 2008). Commercially
available (+/-)-anatoxin-a fumarate diluted in physiological saline (0.9%; controls) was
administered by the i.p. route to 10 males in each treatment group. Although there were no
significant changes in body weight gain or with absolute and relative testes weights, a
statistically significant (p<0.01) reduction in absolute and relative weights of cauda epididymis
was observed in the 0.1 and 0.15 mg/kg treatment groups. A statistically significant (p<0.01)
dose-dependent reduction in sperm count in the cauda epididymis was observed in all treatment
groups compared to control. Histopathological examination of the testes revealed dose-
dependent degeneration in seminiferous tubules, sloughing of germ cells into tubular lumen,
vacuolization in Sertoli cells, intercellular disassociation of spermatogenetic cell lines and loss of
germ cells. Epithelial thickness of seminiferous tubules decreased significantly in all treatment
groups in a dose-dependent manner. The LOAEL was identified as 50 |ig/kg based on reduced
sperm count in cauda epididymis (Yavasoglu et al., 2008).
In a developmental toxicity screening study, groups of 10 and 12 pregnant Crl:CD-
l(ICR) BR mice were administered by gavage doses 0 (vehicle control) or 3 mg/kg-day of
aqueous (+)-anatoxin-a hydrochloride (commercial product, purity not reported) equivalent to 0
or 2.5 mg anatoxin-a/kg, respectively, on GD 6-15 (Fawell and James, 1994; Fawell et al., 1999).
Until GD 18, clinical signs and body weights were recorded, and at that time maternal animals
were sacrificed and necropsied to assess the numbers of implantations and live fetuses, post
implantation loss and fetal body weight, sex ratio and external abnormalities. No treatment-
related maternal effects or effects in the fetuses were observed. However, mean fetal weight in
the treated group was marginally lower than in controls (data not reported). Based on the absence
of adverse effects in dams and fetuses, the NOAEL for maternal and developmental toxicity was
2.5 mg/kg-day of anatoxin-a.
A mammalian embryo toxicity test was conducted by Rodgers et al. (2005) using CD-I
mouse embryos collected on GD 8. Cultured embryos (9-13) were exposed to 0.00002, 0.0002,
0.002 and 0.0051 mg/ml anatoxin-a (racemic and 90% pure) and evaluated for
dysmorphogenesis (abnormal tissue formation). At the end of the culture period, none of the
embryos showed a significant dose-related increase in dysmorphogenesis. Embryos exposed to
0.002 and 0.0051 mg/ml of anatoxin-a showed a perturbation in yolk sac vasculature, such as a
decrease in large caliber vessels and a reduction in arborization (the branching structure at the
end of a nerve fiber) (Rodgers et al., 2005).
Rodgers et al. (2005) conducted an amphibian embryo-larval toxicity test (AMPHITOX)
using toad embryos from Bufo arenarum beginning at Stage 18 or Stage 25. Groups of 10
embryos (in duplicate) were placed in 5 cm glass petri dishes with 10 mL of the AMPHITOX
solution at 20°C for 13 days to monitor for viability and functional impairments. Stage 18
embryos were exposed to 0.03, 0.3, 3.0 or 30 mg/L anatoxin-a and Stage 25 embryos were
exposed to 30 mg/L anatoxin-a, both for 10 days. Results of anatoxin-a exposure in more than
70%) of the embryos affected at the high dose in both exposure periods indicate induction of a
Health Effects Support Document for Anatoxin-a - June 2015
24
-------
dose-dependent transient narcosis. Edema and loss of equilibrium also were observed and
mortality occurred in both embryonic stages. In Stage 18, mortality was observed with 20% of
the exposed embryos in the highest dose group on day 8 and reached 100% between days 10 to
13. Mortality also occurred in the 0.3 and 3.0 mg/L dose groups over the same time period (10
and 13 days). In Stage 25, mortality was observed starting at day 6 of exposure and reached
100%) by day 9.
6.2.4 Chronic Toxicity
No chronic toxicity studies of oral exposure to anatoxin-a were identified.
6.3 Carcinogenicity
Information on carcinogenicity in humans or animals or potential mode(s) of action for
anatoxin-a is not available.
6.4 Other Key Data
6.4.1 Mutagenicity and Genotoxicity
There is limited information regarding mutagenicity or genotoxicity of anatoxin-a.
Preliminary findings by Sieroslawska and Rymuszka (2010) indicate that without metabolic
activation, anatoxin-a was genotoxic in an umuC assay with Salmonella typhimurium TA
1535/pSK1002. UmuC assays are used to detect DNA damage resulting from cell cycle arrest.
Commercial (+/-)-anatoxin-a fumarate (purity not reported) was administered at 0.00025, 0.0005,
0.001 and 0.002 mg/mL doses with a 2-hour exposure time to assess induction and expression of
the umuC - lacZ reporter gene. The lowest dose (0.00025 mg/mL) was the highest concentration
without an effect in the absence of metabolic transformation. When an S9 fraction (the
supernatant fraction with cytosol and microsomes from an organ, usually liver, homogenate by
centrifuging at 9000 g for 20 minutes in a suitable medium) was added to the samples, no effects
were detected (Sieroslawska and Rymuszka, 2010).
6.4.2 Immunotoxicity
No information was located regarding effects of anatoxin-a on immune function in
humans; however, in an in vitro study to assess the effects of anatoxin-a on the viability of
leukocytes, Bownik et al. (2012) found that anatoxin-a induced apoptosis and necrosis in carp
(Cyprinus carpio L.) immune cells. The viability of leukocytes was tested using a CellTiter-
Glo® luminescent Viability Assay to quantify intracellular adenosine triphosphate (ATP) as a
measure of cell metabolic activity. Different concentrations (0.0001, 0.001, 0.005 and 0.010
mg/mL) of anatoxin-a were added to 100 |iL of cell suspension and incubated for 24 hours. The
study found that intracellular ATP levels in leukocytes were slightly reduced at the highest dose
(0.010 mg/L), and no damage was observed at the lower doses. The highest dose also induced
necrosis in leukocytes. Although anatoxin-a had little effect on leukocyte viability, apoptotic
leukocytes were observed at all dose concentrations of anatoxin-a. A concentration-dependent
decrease in the proliferative ability of T and B lymphocytes also was observed at all doses.
Health Effects Support Document for Anatoxin-a - June 2015
25
-------
Rymuszka and Sieroslawska (2010) also found apoptosis in fish immune cells after exposure to
0.001 mg/L of pure anatoxin-a. Fluorescent analysis showed more cells at the apoptotic stage
than at the necrotic stage (Rymuszka and Sierslawska, 2010).
6.5 Physiological or Mechanistic Studies
6.5.1 Noncancer Effects
Data from in vitro studies have shown that (+)-anatoxin-a mimics the action of
acetylcholine at neuromuscular nicotinic receptors (Carmichael et al., 1975, 1979; Biggs and
Dryden, 1977; Aronstam and Witkop, 1981; Swanson et al., 1986). Anatoxin-a is significantly
more potent than acetylcholine and nicotine as an agonist (initiates a physiological response at
peripheral and central sites in the CNS). Anatoxin-a has become an important agent in the
investigation of nicotinic acetylcholine receptors due to its resistance to enzymatic hydrolysis (by
acetylcholinesterase), and because it is 100 times more selective for nicotinic acetylcholine
receptors than for muscarinic acetylcholine receptors (Aronstam and Witkop, 1981). Because
anatoxin-a is not degraded by cholinesterase or other known cellular enzymes, muscle cells
continue to be stimulated, causing fatigue, muscular twitching and paralysis. As observed in
acute lethality animal studies, severe overstimulation of respiratory muscles may result in
respiratory arrest and rapid death (Carmichael et al., 1975, 1977; Devlin et al., 1977; Stevens and
Krieger, 1991b).
Anatoxin-a can affect the cardiovascular system of rats by acting as a nicotinic
cholinergic agonist causing an increase in blood pressure and heart rate (Siren and Feuerstein,
1990; Adeyemo and Siren, 1992; Dube et al., 1996). Anatoxin-a also can affect human and rat
brain neurons (Durany et al., 1999; Thomas et al., 1993; Zhang et al., 1987). Molloy et al. (1995)
have demonstrated that anatoxin-a stimulates the secretory response in bovine adrenal
chromaffin cells (neuroendocrine cells found in the medulla of the adrenal glands), probably
through the activation of neuronal-type nicotinic receptors.
Numerous studies have indicated that anatoxin-a can elicit the release of
neurotransmitters from presynaptic neuromuscular and brain cell terminals (Rowell and
Wonnacott, 1990; Gordon et al., 1992; Soliakov et al., 1995; Clarke and Reuben, 1996;
Wonnacott et al., 2000). Incubation of anatoxin-a with preparations of guinea pig ileum
longitudinal muscle myenteric plexus resulted in a dose-dependent release of acetylcholine
(Gordon et al., 1992). In other studies, anatoxin-a stimulated the release of dopamine from rat
striatal synaptosomes in a dose-dependent manner (Rowell and Wonnacott, 1990; Soliakov et al.,
1995; Clarke and Reuben, 1996; Wonnacott et al., 2000), which suggests that anatoxin-a can
bind to presynaptic nicotinic receptors and trigger neurotransmitter release with increased
stimulation of postsynaptic receptors.
6.5.2 Cancer Effects
No long term bioassay studies on the turnorigenicity of anatoxin-a were identified.
26
Health Effects Support Document for Anatoxin-a - June 2015
-------
6.5.3
Interactions with Other Chemicals
Studies of interactions of anatoxin-a in mixtures with other cyanotoxins and/or
contaminants were not identified.
6.5.4 Structure Activity Relationship
Anatoxin-a is produced as the natural stereoisomer, (+)-anatoxin-a, a nicotinic
acetylcholine receptor agonist that affects both peripheral and central sites in the nervous system
(Huber, 1972; Devlin et al., 1977; Fawell et al., 1999; Viaggiu et al., 2004). Studies have
established that anatoxin-a binds to acetylcholine receptors and mimics the action of
acetylcholine at neuromuscular nicotinic receptors causing neurological effects (Wonnacott and
Gallagher, 2006). In general, nicotinic agonists, such as anatoxin-a, form hydrogen bonds in the
planar region of the receptor and have a bulky cationic group around 5.9 A from the hydrogen
bond (Beers and Reich, 1970; Chothia and Pauling, 1970; Spivak and Albuquerque, 1982).
Numerous in vitro studies (Fawell and James, 1994; Fawell et al., 1999; MacPhail et al.,
2007) of acetylcholine receptor response in rat phrenic nerve, chick biventer cervicis muscle,
guinea pig ileum and in mice intravenously demonstrated that anatoxin-a was 7 to 136 times
more potent than nicotine. In frog (Xenopus) oocytes, mouse M10 cells, rat hippocampal
synaptosomes and fetal rat hippocampal neurons, (+)-anatoxin-a agonist potency was 3 to 50
times greater than nicotine and around 20 times greater than acetylcholine at neuronal nicotinic
acetylcholine receptors (Thomas et al., 1993).
Assays of contracture potency in preparations of frog rectus abdominis muscle have
shown that natural (+)-anatoxin-a can exhibit at least a 2.5- and 150-fold greater potency than
racemic and (-)-anatoxin-a, respectively (Spivak and Albuquerque, 1982; Spivak et al., 1983;
Swanson et al., 1986). However, in vivo lethality assays in mice have shown comparable potency
differences (LD50 values of 386 and 913 (J,g/kg for (+)-anatoxin-a hydrochloride and racemic
anatoxin-a hydrochloride, respectively) (Valentine et al., 1991). No clinical signs or deaths were
observed in mice treated similarly with doses of (-)-anatoxin-a hydrochloride as high as 73,000
|ig/kg, further demonstrating the potency of (+)-anatoxin-a (2.4 times as potent as racemic and
189 times as potent as (-)-anatoxin-a).
Racemic anatoxin-a is considerably more potent than acetylcholine and nicotine as an
agonist at neuromuscular nicotinic acetylcholine receptors. Compared to acetylcholine, anatoxin-
a binds tightly to the nicotinic acetylcholine receptor with a 3.6 times greater affinity (Swanson
et al., 1986). After complete inhibition of acetylcholinesterase activity in frog rectus abdominis
muscle preparations, anatoxin-a showed an 8-fold greater potency in measures of contracture
than acetylcholine (Swanson et al., 1986).
Anatoxin-a derivatives, such as 2,3-epoxy-anatoxin-a, 4-hydroxy- and 4-oxo-derivatives
and the reduced derivatives, dihydroanatoxin-a and dihydrohomoanatoxin-a, although non-toxic,
may retain anatoxin-a's toxicity. Dihydroanatoxin-a has about 10% of the toxicity of anatoxin-a
(Mann et al., 2012). The n-methylation of anatoxin-a greatly reduces the acetylcholine-
mimicking effect at nicotinic cholinergic receptors as shown in neuromuscular and neuronal
27
Health Effects Support Document for Anatoxin-a - June 2015
-------
assays of structure activity relationships (Aracava et al., 1987; Costa et al., 1990; Stevens and
Krieger, 1990; Swanson et al., 1989, 1991; Wonnacott et al., 1991).
6.6 Hazard Characterization
6.6.1 Synthesis and Evaluation of Major Noncancer Effects
Anatoxin-a is known to cause acute neurotoxicity manifested as loss of coordination,
muscular fasciculations, convulsions and death by respiratory paralysis. Anatoxin-a mimics
acetylcholine at neuromuscular nicotinic receptors (Aronstam and Witkop, 1981; Biggs and
Dryden, 1977; Carmichael et al., 1975, 1979; Swanson et al., 1986). The (+) anatoxin-a form is
more potent than acetylcholine and is not degraded by acetylcholinesterase. Therefore, an
interaction with the nicotinic acetylcholine receptors causes persistent stimulation of the muscle
cells (Swanson et al., 1986; Thomas et al., 1993).
Health effects data of anatoxin-a in humans were not found. Several cases have been
reported of nonlethal poisonings in humans caused by ingestion of contaminated water with
Anabaena sp., however, detection of anatoxin-a was not reported. Acute gastrointestinal
disorders were the most commonly-reported effects (Schwimmer and Schwimmer, 1968).
A few acute and short-term studies and one subchronic study have provided information
on in vivo effects of anatoxin-a in orally-exposed laboratory animals. However, these studies
have yielded only limited dose-response data on systemic effects. The test substance varied
among the studies with the use of extracts, racemic hydrochloride salts and (+) anatoxin-a as the
hydrochloride salt. An LD50 of 13.3 mg anatoxin-a/kg based on neurotoxicity was identified
from lethality assays in mice (Fitzgeorge et al., 1994; Stevens and Krieger, 1991b).
Short-term oral toxicity studies provide some information on systemic toxicity and
developmental toxicity in mice (Fawell and James, 1994; Fawell et al., 1999). In a 5-day mouse
study, four dose levels were used (1.2, 2.5, 6.2 and 12.3 mg/kg-day by gavage). However, the
study was limited by the small number of animals tested (2 mice per sex per dose), the lack of
concurrent controls and by the extent and type of endpoints evaluated (clinical signs, body
weight, food consumption and necropsy). Because dose-related mortality was observed at the
highest doses (1 of 4 mice at 6.2 mg/kg-day and in all mice at 12.3 mg/kg-day), the authors
identified a NOAEL as 2.5 mg/kg-day.
In the 28-day toxicity study (Fawell and James, 1994; Fawell et al., 1999), the NOAEL is
0.1 mg/kg-day and LOAEL is 0.5 mg/kg-day based on mortality (one death in 10 treated males).
However, because no cause of death was determined in the postmortem examination, the authors
indicated that the true NOAEL could have been 2.5 mg/kg-day had the researchers been able to
determine the cause of the death in the mid dose group. Given that no cause of death could be
determined, a "relationship to treatment could not be ruled out." There were significant changes
in mean red cell hemoglobin at the mid and high dose that the authors did not consider to be
toxicologically significant. There were no deaths in the Fawell et al. (1999) developmental study
of an unidentified number of female mice that received a 2.5 mg/kg/day dose of anatoxin-a.
Health Effects Support Document for Anatoxin-a - June 2015
28
-------
A 7-week subchronic drinking water toxicity study found no treatment-related effects of
anatoxin-a (Astrachan and Archer, 1981; Astrachan et al., 1980). This study was limited by the
use of only two dose levels (0.05 and 0.5 mg/kg-day), a lack of comprehensive examinations,
especially hematology (two indices), blood chemistry (four serum enzymes) and histology (seven
tissues), and inadequate reporting (composition of the extract). The high dose (0.5 mg/kg) caused
an approximately 30 to 50% increase in white blood cell count throughout week 5 of the
observation period. There was also an initial (1 week) increase in white cell count compared to
controls at the low dose, but it was not observed in the three-, five- or seven- week blood
samples.
No data are available on the chronic oral toxicity of anatoxin-a.
6.6.2 Synthesis and Evaluation of Major Carcinogenic Effects
No information on carcinogenicity of anatoxin-a in humans or animals or on potential
carcinogenic precursor effects was identified.
6.6.2.1 Mode of Action and Implications in Cancer Assessment
No information regarding the mode(s) of action of carcinogenicity in humans or animals
was identified.
6.6.2.2 Weight of Evidence Evaluation for Carcinogenicity
In accordance with the Guidelines for Carcinogen Risk Assessment (U.S. EPA, 2005a), at
the present time there are inadequate data to assess carcinogenic potential of anatoxin-a.
6.6.2.3 Potentially Sensitive Populations
No information was identified on the degree to which sensitive populations might differ
from the general population in the disposition of, or response to, anatoxin-a. Likewise, there is
no information on possible gender differences in the disposition of, or response to, anatoxin-a.
Anatoxin-a may interact with anticholinergic agents recommended for the treatment of
various medical conditions, including glaucoma, atony of the smooth muscle of the intestinal
tract and urinary bladder, myasthenia gravis and termination of the effects of competitive
neuromuscular blocking agents (Taylor, 1996). For example, anatoxin-a along with atropine
sulphate, a common anesthetic that blocks the action of acetylcholine at muscarinic receptors,
could attenuate the effects of the anesthetic (Cook et al, 1990). Those exposed to anatoxin-a
using anticholinergic agents for therapeutic purposes may experience adverse side effects.
Health Effects Support Document for Anatoxin-a - June 2015
29
-------
7.0 DOSE-RESPONSE ASSESSMENT
7.1 Dose-Response for Noncancer Effects
The majority of experimental studies of anatoxin-a are in vitro and pertain to its mode of
neurotoxic action. These studies have established that anatoxin-a binds to acetylcholine receptors
and mimics the action of acetylcholine at neuromuscular nicotinic receptors (Aronstam and
Witkop, 1981; Biggs and Dryden, 1977; Carmichael etal., 1975, 1978, 1979; Swanson etal.,
1986). With sufficient exposure, acetylcholine accumulation occurs at cholinergic neuroeffector
junctions (muscarinic effects), at skeletal myoneural junctions and in autonomic ganglia
(nicotinic effects). Acute in vivo neurotoxicity studies of anatoxin-a in animals have identified
tremors, altered gait, convulsions and death by respiratory paralysis as the most common
symptoms. Limited information has been identified on in vivo neurotoxicity at sublethal doses,
including the lack of effects of acute intravenous exposure on motor activity, coordination,
sensory/motor reflexes and other central nervous system responses in mice as well as no
observed effects of gestational intraperitoneal exposure on postnatal neuro-developmental
maturation in mice.
Oral toxicity studies in laboratory animals include a single-dose lethality assay in mice
(Stevens and Krieger, 1991b), 28-day studies in mice, and developmental GD 6 to 15 day
toxicity studies in mice (Fawell et al., 1999), plus a 7-week study in rats (Astrachan and Archer,
1981). However, the data from these oral toxicity studies are insufficient for deriving an RfD due
to inconsistencies in the effects reported, inadequate experimental design and reporting, and the
use of too few dose levels and study endpoints.
7.1.1 RfD Determination
Available acute oral toxicity data for anatoxin-a are inadequate to support derivation of
an acute RfD. Experimental data on the acute oral toxicity in animals are limited to two lethality
assays in mice that determined an LD50 value of 13.3 mg anatoxin-a/kg and identified
neurotoxicity as the cause of death (Fitzgeorge et al., 1994; Stevens and Krieger, 1991b).
Information on toxicity of anatoxin-a is available from a short-term oral 28-day systemic
toxicity study and a developmental toxicity study in mice (Fawell and James, 1994; Fawell et al.,
1999). In the 28-day study, groups of 10 mice/sex at dose levels of 0, 0.1, 0.5 and 2.5 mg/kg-day
identified a NOAEL of 0.1 mg/kg-day. The NOAEL was based on lethality in 1 of 10 animals
exposed. The authors did not identify the cause of two of the three deaths and other effects
reported in treated animals, such as minor but statistically significant hematology changes, were
not considered toxicologically significant by the authors.
A single subacute oral toxicity study (7-week drinking water study in rats) provides
information on the oral toxicity of anatoxin-a (Astrachan and Archer, 1981; Astrachan et al.,
1980). A NOAEL of 0.05 mg/kg-day was identified and a LOAEL of 0.5 mg/kg based on an
increase in white blood cell counts over the first 5 weeks of the study. However, the
toxicological significance of this effect is not clear given that it was not apparently evaluated in
any of the other studies and the authors did not consider it to be adverse.
30
Health Effects Support Document for Anatoxin-a - June 2015
-------
7.1.2 RfC Determination
No information is available on the toxicity of inhaled anatoxin-a.
7.2 Dose-Response for Cancer Effects
There is no information or dose-response data available regarding the carcinogenicity of
anatoxin-a in reported incidental human exposures (e.g., bathing, swimming, dish washing) or
cancer studies in animals.
31
Health Effects Support Document for Anatoxin-a - June 2015
-------
8.0 RESEARCH GAPS
Other than the effects of anatoxin-a on the niconinergic acetyl choline receptors of the central
and peripheral nervous system, there are few studies of systemic effects from oral exposures of
laboratory animals to anatoxin-a. This chapter provides a summary of knowledge gaps and
research needs that limit a complete assessment of human health consequences from exposure to
anatoxin-a in drinking water. The key research gaps listed below were identified during the
development of this document and are not intended to be an exhaustive list. Additional research
is needed, including:
• Purification and toxin synthesis.
• Quantification for the absorption, distribution and elimination of anatoxin-a in humans or
animals following oral, inhalation or dermal exposure.
• Health risks posed by repeated, low-level exposures of laboratory animals to anatoxin-a.
• The chronic toxicity of anatoxin-a.
• The systemic, immunotoxic and developmental/reproductive toxicity of anatoxin-a
following oral exposure.
• The carcinogenic potential of anatoxin-a.
• Potential health risks from exposure to mixtures of anatoxin-a and other cyanotoxins or
other chemical stressors present in ambient and drinking water supplies.
• Relative potency of anatoxin-a relative to other agonists for nicotinic acetylcholine
receptors.
• Populations that might be sensitive to anatoxin-a exposure via the oral, dermal and/or
inhalation routes.
32
Health Effects Support Document for Anatoxin-a - June 2015
-------
9.0 REFERENCES
Adeyemo, O. M. and Siren, A. L. 1992. Cardiorespiratory changes and mortality in the
conscious rat induced by (+)- and (+)-anatoxin-a. Toxicon. 30(8): 899-905.
Adhikary, S. 1996. Ecology of Freshwater and Terrestrial Cyanobacteria. Journal of Scientific &
Industrial Research, 55(8-9): 753-762.
Al-Sammak, M. A., Hoagland, K. D., Cassada, D., and Snow, D. D. 2014. Co-occurrence of the
cyanotoxins BMAA, DAB A, and anatoxin-a in Nebraska reservoirs, fish, and aquatic plants.
Toxins (Basel), 6(2): 488-508.
Aracava, Y., Swanson, K. L., Rapoport, H., Aronstam, R. S., and Albuquerque, E. X. 1987.
Anatoxin-a analog: Loss of nicotinic agonism and gain of antagonism at the acetylcholine-
activated channels. Federation Proceedings, 46: 861.
Aronstam, R. S. and Witkop, B. 1981. Anatoxin-a interactions with cholinergic synaptic
molecules. Proceedings of the National Academy of Sciences, 78(7): 4639-4643.
Astrachan, N. B., Archer, B. G. and Hilbelink, D. R. 1980. Evaluation of the subacute toxicity
and teratogenicity of anatoxin-a. Toxicon, 18(5-6): 684-688.
Astrachan, N. B. and Archer, B. G. 1981. Simplified monitoring of anatoxin-a by reverse-phase
high performance liquid chromatography and the sub-acute effects of anatoxin-a in rats. In:
W. W. Carmichael, (Ed). The Water Environment: Algal Toxins and Health. Plenum Press,
New York, NY: 437-446.
Backer, L., Landsberg, J., Miller, M., Keel, K., and Taylor, T. 2013. Canine Cyanotoxin
Poisonings in the United States (1920-2012): Review of Suspected and Confirmed Cases
from Three Data Sources. Toxins, 5(9): 1597-1628.
Beattie, K. A., Kaya, K., Sano, T., and Codd, G. A. 1998. Three dehydrobutyrine (Dhb)-
containing microcystins from the cyanobacterium Nostoc sp. Phytochemistry, 47(7): 1289-
1292.
Beers, W. H. and Reich, E. 1970. Structure and activity of acetylcholine. Nature, 228: 917-922.
Behm, D. 2003. Coroner cites algae in teen's death. Milwaukee Journal Sentinel. September 6.
Berry, J., Jaja-Chimedza, A., Davalos-Lind, L. and Lind, O. 2012. Apparent bioaccumulation of
cylindrospermopsin and paralytic shellfish toxins by finfish in Lake Catemaco (Veracruz,
Mexico). Food Additives and Contaminants, 29(2): 314-321.
Biggs, D. F. and Dryden, W. F. 1977. Action of anatoxin-a at the neuromuscular junction.
Proceedings of the Western Pharmacology Society, 20: 461-466.
Health Effects Support Document for Anatoxin-a - June 2015
33
-------
Bownik A, Rymuszka A, Sieroslawska A, Skowronski T. 2012. Anatoxin-a induces apoptosis of
leukocytes and decreases the proliferative ability of lymphocytes of common carp (Cyprinus
carpio L.) in vitro. Polish Journal of Veterenary Science, 15(3): 531-535.
Burns, J. 2008. Toxic cyanobacteria in Florida waters. Advances in Experimental Medicine and
Biology, 619: 127-37.
Caraco, N.F. and Miller, R. 1998. Effects of CO2 on competition between a cyanobacterium and
eukaryotic phytoplankton. Canadian Journal of Fisheries and Aquatic Sciences, 55: 54-62.
Carbis, C. R., Rawlin, G. T., Grant, P., Mitchell, G. F., Anderson, J. W. and McCauley, I. 1997.
A study of feral carp Cyprinus carpio L., exposed to Microcystis aeruginosa at Lake
Mokoan, Australia, and possible implication on fish health. Journal of Fish Diseases, 20: 81-
91.
Carey, C. C., Ibelings, B. W., Hoffmann, E. P. and Brookes, D. P. 2012. Eco-physiological
adaptations that favour freshwater cyanobacteria in a changing climate. Water Research, 46:
1394-1407.
Carmichael, W. W., Biggs, D. F. and Gorham, P. R. 1975. Toxicology and pharmacological
action of Anabaena flos-aquae toxin. Science, 187: 542-544.
Carmichael, W. W., Gorham, P. R. and Biggs, D. F. 1977. Two laboratory case studies on the
oral toxicity to calves of the freshwater cyanophyte (blue-green alga) Anabaena flos-aquae
NRC-44-1. Canadian Veterinary Journal, 18(3): 71-75.
Carmichael, W. W. and Gorham, P. R. 1978. Anatoxins from clones of Anabaena flos-aquae
isolated from lakes of western Canada. Mitteilungen Internationale Vereinigungfiir
Theoretische undAngewandte Limnologie .21: 285-295.
Carmichael, W. W., Biggs, D. F. and Peterson, M. A. 1979. Pharmacology of anatoxin-a,
produced by the freshwater cyanophyte Anabaena flos-aquae NRC-44-1. Toxicon, 17(3):
229-236.
Carmichael, W. W., Azevedo, S. M. F. O. and An, J.S. 2001. Human fatalities from
cyanobacteria: Chemical and biological evidence for cyanotoxins. Environmental Health
Perspectives, 109(7): 663-668
Carmichael, W.W., Yuan, M. and Friday, C.F. 2004. Human mortality from accidental ingestion
of toxic cyanobacteria - A case re-examined. 6th International Conference on Toxic
Cyanobacteria, Bergen, Norway. June 21-25. (poster presentation)
Castenholz, R. W. and Waterbury, J. B. 1989. In: J. T. Staley, M. P. Bryant, N. Pfennig and J. G.
Holt (Eds). Bergey's Manual of Systematic Bacteriology. Vol. 3, Williams & Wilkins,
Baltimore, MD, 1710-1727.
Health Effects Support Document for Anatoxin-a - June 2015
34
-------
Castenholz, R. W. 1973. Ecology of blue-green algae in hot springs. In: N. G. Carr and B. A.
Whitton (Eds). The Biology of Blue-Green Algae. Blackwell Scientific Publications, Oxford,
379-414.
Chemical Book. 2012. CAS Index. Retrieved September 25, 2012 from the World Wide Web:
http ://www. chemi calbook. com/Search_EN. aspx?key word
Chothia, C. and Pauling, P. 1970. The conformation of cholinergic molecules at nicotinic nerve
receptors. Proceedings of the National Academy of Sciences, 65(3): 477-482.
Clarke, P. B. S. and Reuben, M. 1996. Release of 3H-noradrenaline from rat hippocampal
synaptosomes by nicotine: Mediation by different nicotinic receptor subtypes from striatal
3H-dopamine release. British Journal of Pharmacology, 117(4): 595-606.
Codd, G. A. and Poon, G. K. 1988. Cyanobacterial toxins. Proceedings of the Phytochemical
Society of Europe, 28: 283-296.
Codd, G. 1995. Cyanobacterial Toxins: Occurrence, Properties and Biological Significance.
Water Science and Technology, 32(4): 149-156.
Cook, L., Nickolson, V. J., Steinfels, G. F., Rohrbach, K. W. and Denoble, V. J. 1990. Cognition
enhancement by the acetylcholine releaser DuP 996. Drug Development Research, 19: 301—
314.
Costa, A. C. S., Swanson, K. L., Aracava, Y., Aronstam, R. S. and Albuquerque, E. X. 1990.
Molecular effects of dimethylanatoxin on the peripheral nicotinic acetylcholine receptor.
Journal of Pharmacology and Experimental Therapeutics, 252(2): 507-516.
De Senerpont Domis, L., Mooij, W. M. and Huisman, J. 2007. Climate-induced shifts in an
experimental phytoplankton community: a mechanistic approach. Hydrobiologia, 584: 403-
413.
Devlin, J. P., Edwards, O. E., Gorham, P. R., Hunter, N. R., Pike, R. K. and Stavric, B. 1977.
Anatoxin-a, a toxic alkaloid from Anabaena flos-aquae NRC-44h. Canadian Journal of
Chemistry, 55(8): 1367-1371.
Dor, I. and Danin, A. 1996. Cyanobacterial desert crusts in the Dead Sea Valley, Israel.,
Algological Studies, 83: 197-206.
Downing, J. A., Watson, S. B. and McCauley, E. 2001. Predicting Cyanobacteria dominance in
lakes. Canadian Journal of Fisheries and Aquatic Sciences, 58(10): 1905-1908.
Drake, J. L., Carpenter, E. J., Cousins, M., Nelson, K. L., Guido-Zarate, A. and Loftin, K. 2010.
Effects of light and nutrients on seasonal phytoplankton succession in a temperate eutrophic
coastal lagoon. Hydrobiologia, 654: 177-192.
Health Effects Support Document for Anatoxin-a - June 2015
35
-------
Dube, S. N., Mazumder, P. K., Kumar, D., Rao, P. V. L. and Bhasker, A. S. B. 1996.
Cardiorespiratory and neuromuscular effects of freshwater cyanophyte Anabaena flos aquae
in rats. Defense Science Journal, 46(3): 135-141.
Durany, N., Riederer, P. and Deckert, J. 1999. The CNS toxin anatoxin-a interacts with a4fi2-
nicotinic acetylcholine receptors in human cortex. Alzheimer's Reports. 2(5): 253-266.
Duy, T.N., Lam, P.K.S., Shaw, G.R. and Connell, D.W. 2000. Toxicology and risk assessment of
freshwater cyanobacterial (blue-green algal) toxins in water. Reviews of Environmental
Contamination and Toxicology, 163: 113-186.
Edwards, C., Beattie, K. A., Scrimgeour, C. M. and Codd, G. A. 1992. Identification of anatoxin-
a in benthic cyanobacteria (blue-green algae) and in associated dog poisonings at Loch
Insh, Scotland. Toxicon, 30(10): 1165-1175.
Elliott, J. A. 2010. The seasonal sensitivity of cyanobacteria and other phytoplankton to changes
in flushing rate and water temperature. Global Change Biology, 16: 864-876.
Elser, J. J., Bracken, M. E. S. and Cleland, E. E. 2007. Global analysis of nitrogen and
phosphorus limitation of primary producers in freshwater, marine and terrestrial ecosystems.
Ecology Letters, 10: 1124-1134
Eriksson, J. E., Paatero, G. I. L., Meriluoto, J. A. O., et al. 1989. Rapid microfilament
reorganization induced in isolated rat hepatocytes by microcystin-LR, a cyclic peptide toxin.
Experimental Cell Research, 185(1): 86-100.
Ettoumi, A., Khalloufi, F., El Ghazali, I., Oudra, B., Amrani, A., Nasri, H. and Bouaicha, N.
2011. Bioaccumulation of Cyanobacterial Toxins in Aquatic Organisms and its
Consequences for Public Health. In: G. Kattel (Ed). Zooplankton and Phytoplankton, Nova
Science Publishers, Inc., New York, NY pp. 1-34.
Falconer, I. R. and Yeung, S. K. 1992. Cytoskeletal changes in hepatocytes induced by
Microcystis toxins and their relation to hyperphosphorylation of cell proteins. Chemico-
BiologicalInteractions, 81(1-2): 181-196.
Falconer, I. R. 2005. Cyanobacterial Toxins of Drinking Water Supplies: Cylindrospermopsins
andMicrocystins. CRC Press, Boca Raton, FL pp. 263
Fawell, J. F. and James, H. A. 1994. Toxins from blue-green algae: Toxicological assessment of
anatoxin-a and a method for its determination in reservoir water. FWR Report No.
FR0492/DOE372.
Fawell, J. K., Mitchell, R. E., Hill, R. E. and Everett, D. J. 1999. The toxicity of cyanobacterial
toxins in the mouse: II Anatoxin-a. Human and Experimental Toxicology, 18(3): 168-173.
Health Effects Support Document for Anatoxin-a - June 2015
36
-------
Fay, P. 1965. Heterotrophy and nitrogen fixation in Chlorogloea fritschii. Journal of General
Microbiology, 39: 11-20.
Fitzgeorge, N. L. M., Clark, S. A. and Kelvin, C. W. 1994. Routes of intoxication. In: G. A.
Codd, T. M. Jeffreies, C. W. Kelvin and E. Potter, (Eds.). Detection Methods for
Cyanobacterial (Blue-Green Algal) Toxins and First International Symposium on Detection
Methods for Cyanobacterial (Blue-Green Algal) Toxins. Royal Society of Chemistry,
Cambridge, U.K. p. 69-74. (As cited in Kuiper-Goodman et al., 1999 and WHO 1999)
Funari, E. and Testai, E. 2008. Human Health Risk Assessment Related to Cyanotoxins
Exposure. Critical Reviews in Toxicology, 38: 97-125.
Furey, A., Crowley, J., Hamilton, B., Lehane, M., James, K.J. 2005. Strategies to avoid the mis-
identification of anatoxin-a using mass spectrometry in the forensic investigation of acute
neurotoxic poisoning. J Chromatogr A. Jul 29;1082(1):91.
Gordon, R. K., Gray, R. R., Reaves, C. B., Butler, D. L. and Chiang, P. K. 1992. Induced release
of acetylcholine from guinea pig ileum longitudinal muscle-myenteric plexus by anatoxin-a.
Journal of Pharmacology and Experimental Therapeutics, 263(3): 997-1001.
Graham, J., K. Loftin, M. Meyer, and A. Ziegler. 2010. Cyanotoxin mixtures and taste-and-odor-
compounds in cyanobacterial blooms from the midwestern United States. Environmental
Science and Technology 44: 7361-7368.
Gudasz, C., Bastviken, D., Steger, K., Premke, K., Sobek, S. and Tranvik, L.J. 2010.
Temperature controlled organic carbon mineralization in lake sediments. Nature, 466: 478-
481.
Gunn, G. J., Rafferty, A. G., Rafferty, G. C., et al. 1992. Fatal canine neurotoxicosis attributed to
blue-green algae (cyanobacteria). Veterinary Record, 130(14): 301-302.
Health Canada. 2012. Toxicity Profile for Cyanobacterial Toxins. Prepared for Water Quality
and Science Division of Health Canada by MTE GlobalTox. MTE File No.: 36348-100.
January 27, 2012. 48 pages.
Hedman, C. J., Krick, W. R., Kamer Perkins, D. A., Harrahy, E. A. and Sonzogni, W. C. 2008.
New measurements of cyanobacterial toxins in natural waters using high performance liquid
chromatography coupled to tandem mass spectrometry. Journal of Environmental Quality,
37(5): 1817-24.
Heussner, A. H., Mazija, L., Fastner, J. and Dietrich, D. R. 2012. Toxin content and cytotoxicity
of algal dietary supplements. Toxicology and Applied Pharmacology, 265: 263-271.
Hitzfeld, B., Hoeger, S. J. and Dietrich, D. R. 2000. Cyanobacterial Toxins: Removal during
Drinking Water Treatment, and Human Risk Assessment. Environmental Health
Perspectives, 108(Supplement 1): 113-122.
Health Effects Support Document for Anatoxin-a - June 2015
37
-------
Honjo M., Matsui, K., Ueki, M., Nakamura, R., Fuhrman, J. and Kawabata, Z. 2006. Diversity
of vims-like agents killing Microcystis aeruginosa in a hyper-eutrophic pond. Journal of
Plankton Research, 28: 407.
Huber, C. S. 1972. The crystal structure and absolute configuration of 2,9-diacetyl-9-
azabicyclo[4,2,l]non-2,3-ene. Acta Crystallographica Section B, B28(8): 2577-2582.
Hudnell, H. K. (editor). 2008. Cyanobacterial Harmful Algae Blooms, State of the Science and
Research Needs. Proceedings of the Interagency, International Symposium on
Cyanobacterial Harmful Algal Blooms. RTP North Carolina, Sept. 2005. Advances in
Experimental Medicine & Biology, 619: 948
Hudnell, H. K. 2010. The state of U.S. freshwater harmful algal blooms assessments policy and
legislation. Toxicon, 55: 1024-1034.
Huisman, J., Matthijs, H. C. P. and Visser, P. M. 2005. Harmful Cyanobacteria. Springer,
Dordrecht.
ILS (Integrated Laboratory Systems). 2000. Cylindrospermopsin: Review of Toxicological
Literature. Prepared by Integrated Laboratory Systems for National Toxicology Program,
NIEHS, USEPA. December 2000. 37 pages.
Jaag, O. 1945. Untersuchungen fiber die Vegetation and Biologie der Algan des nackten
Gesteins in den Alpen, im Jura and im schweizerischen Mittelland. Kryptogamenflora der
Schweiz, Band IX, Heft 3. Kommissionsverlag Buchdruckerei Btichler and Co., Bern.
Jarema, K.A. and R.C. MacPhail. 2003. Comparative effects of weekly exposures to anatoxin-a
and nicotine on the operant performance of rats. Toxicol. Sci. 72 (Suppl. 1):74.
Jensen, H. S., and Andersen, F. O. 1992. Importance of temperature, nitrate, and pH for
phosphate release from aerobic sediments of 4 shallow, eutrophic lakes. Limnology and
Oceanography, 37: 577-589.
Jensen, G. S., Ginsberg, D. I. and Drapeau, C. 2001. Blue-green algae as an immuno-enhancer
and biomodulator. Journal of the American Medical Association, 3: 24-30.
Jeppesen, E., Kronvang, B., Meerhoff, M., et al. 2009. Climate change effects on runoff,
catchment phosphorus loading and lake ecological state, and potential adaptations. Journal of
Environmental Quality, 38: 1930-1941.
Jeppesen, E., Meerhoff, M., Holmgren, K., et al. 2010. Impacts of climate warming on lake fish
community structure and dynamics, and potential ecosystem effects. Hydrobiologia, 646:
73-90.
Health Effects Support Document for Anatoxin-a - June 2015
38
-------
Kann, E. 1988. Zur Autokologie benthischer Cyanophyten in reinen europaischen Seen and
Fliessgewassem. Arch. Hydrobiol. Suppl. 80, Algological Studies, 50-53: 473-495.
Klitzke., S., Beusch, C. and Fastner, J. 2011. Sorption of the cyanobacterial toxins
cylindrospermopsin and anatoxin-ato sediments. Water Research 45: 1338-1346.
Kosakowska, A., Nedzi, M. and Pempkowiak, J. 2007. Responses of the toxic cyanobacterium
Microcystis aeruginosa to iron and humic substances Plant Physiology and Biochemistry, 45:
365-370.
Kosten, S., Huszar, V.L.M., Mazzeo, N., Scheffer, M., Sternberg, S.L. and Jeppesen, E. 2009.
Lake and watershed characteristics rather than climate influence nutrient limitation in
shallow lakes. Ecological Applications, 19, 1791-1804.
Kosten, S., Roland, F., Da Motta Marques, D.M.L., et al. 2010. Climate-dependent CO2
emissions from lakes. Global Biogeochemical Cycles, 24, GB2007.
Kosten, S., Huszar, V. L. M, Cares, E. B., Costa, L. S., Van Donk, E., Hansson, L. A., Jeppesen,
E., Kruk, C., Lacerot, G., Mazzeo, N., Meester, L. D., Moss, B., Lurling, M, Noges, T.,
Romo, S. and Scheffer, M. 2011. Warmer climates boost cyanobacterial dominance in
shallow lakes. Global Change Biology, 18: 118-126.
Laamanen, M. 1996. Cyanoprokaryotes in the Baltic Sea ice and winter plankton. Arch.
Hydrobiol. Suppl. 117, Algological Studies, 83: 423-433.
Lewis, R. J. 2000. Sax's Dangerous Properties of Industrial Materials, Vol. 1-3, 10th ed., John
Wiley & Sons Inc., New York, NY. p. 257.
Lewis, W.M., Wurtsbaugh, W.A. and Paerl, H.W. 2011. Rationale for control of anthropogenic
nitrogen and phosphorus in inland waters. Environ Sci Technol. 45:10030-10035.
MacPhail, R. C., Farmer, J. D., Jarema, K. A., and Chernoff, N. 2005. Nicotine effects on the
activity of mice exposed prenatally to the nicotinic agonist anatoxin-a. Neurotoxicology and
Teratology, 27(4): 593-598.
MacPhail, R. C., Farmer, J.D., et al. 2007. Effects of acute and weekly episodic exposures to
anatoxin-a on the motor activity of rats: comparison with nicotine. Toxicology 234(1-2): 83-
89.
Magalhaes, V. F., R. M. Soares, and S. M. F. O. Azevedo. 2001. Microcystins contamination in
fish from the Jacarepagua Lagoon (RJ, Brazil): Ecological implication and human health
risk. Toxicon, 39: 1077-1085.
Mann, S., Lombard, B., Loew, D., Mejean, A., and Ploux, O. 2011. Insights into the reaction
mechanism of the prolyl-acyl carrier protein oxidase involved in anatoxin-a and
homoanatoxin-a biosynthesis. Biochemistry, 50(33): 7184-97.
Health Effects Support Document for Anatoxin-a - June 2015
39
-------
Mann S, Cohen M, Chapuis-Hugon F, Pichon V, Mazmouz R, Mejean A, Ploux O. 2012.
Synthesis, configuration assignment, and simultaneous quantification by liquid
chromatography coupled to tandem mass spectrometry, of dihydroanatoxin-a and
dihydrohomoanatoxin-a together with the parent toxins, in axenic cyanobacterial strains and
in environmental samples. Toxicon, 60(8): 1404-14.
Matsunaga, S., Moore, R. E., Niemczura, W. P. and Carmichael, W. W. 1989 Anatoxin-a(s), a
potent anticholinesterase from Anabaena flos-aquae. Journal of the American Chemical
Society, 111: 8021-8023.
McCarthy, J. C. 1967. Effects of litter size and maternal weight on foetal and placental weight in
mice. Jouranl of Reproduction and Infertility, 14(3): 507-510.
Metcalf, J., Richer, R., Cox, P. and Codd, G. 2012. Cyanotoxins in desert environments may
present a risk to human health. Science of the Total Environment, 421-422: 118-123.
Mohamed, Z. 2008. Toxic cyanobacteria and cyanotoxins in public hot springs in Saudi Arabia.
Toxicon. 51: 17-27.
Molloy, L., Wonnacott, S., Gallagher, T., Brough, P.A. and Livett, B.G. 1995. Anatoxin-a is a
potent agonist of the nicotinic acetylcholine receptor of bovine adrenal chromaffin cells. Eur
J Pharmacol. May 26;289(3):447-53.
Moustaka-Gouni, M., Kormas, K. A.,Vardaka, E., Katsiapi, M., and Gkelis, S. 2009.
Raphidiopsis mediterranea Skuja represents non-heterocytous life-cycle stages of
Cylindrospermopsis raciborskii (Woloszynska) Seenayya et Subba Raju in Lake Kastoria
(Greece), its type locality: evidence by morphological and phylogenetic analysis. Harmful
Algae, 8(6): 864-872.
Namikoshi, M., Murakamia, T., Watanabe, M. F., Yamada, T. O. J., Tsujimura, S, Nagaia, H.,
Oishie, S. (2003): Simultaneous production of homoanatoxin-a, anatoxin-a, and a new non-
toxic 4-hydroxyhomoanatoxin-a by the cyanobacterium Raphidiopsis mediterranea Skuja.
Toxicon 42: 533-538.
NRC (National Research Council). 1983. Risk Assessment in the Federal Government:
Managing the Process. National Academy Press, Washington, DC.
O'Brien, K. R., Burford, M. A. and Brookes, J. D. 2009. Effects of light history on primary
productivity in a Cylindrospermopsis raciborskii-dominated reservoir. Freshwater Biology,
54: 272-282.
Ohio EPA. 2010. Grand Lake St. Marys Algal Toxin Sampling Data, Division of Surface Water.
http://www.lakeimprovement.com/sites/default/files/sampling-data-update.pdf
Osswald, J., Rellan, S., Carvalho, A. P., Gago, A. and Vasconcelos, V. 2007. Acute effect of
anatoxin-a producing cyanobacteria on juvenile fish Cyprinus carpio. Toxicon, 49: 693-698.
Health Effects Support Document for Anatoxin-a - June 2015
40
-------
Osswald, J., Azevdeo, J., Vasconcelos, V., and Guilhermino, L. 2011. Experimental
determination of the bioconcentraion factors for anatoxin-a in juvenile rainbow trout
{Oncorhynchus mykiss). Proceedings of the International Academy of Ecology and
Environmental Sciences. 1(2): 77-86.
Paerl H. W. and Huisman, J. 2008. Blooms like it hot. Science, 320: 57-58.
Paerl, H., Xu, H., McCarthy, M., Zhu, G., Qin, B., Li, Y. and Gardner, W. 2011. Controlling
harmful cyanobacterial blooms in a hyper-eutrophic lake (Lake Taihu, China): The need for a
dual nutrient (N & P) management strategy. Water Research, 45(5): 1973-1983.
Paerl, H. W. and Otten, T. G. 2013a. Blooms bite the hand that feeds them. Science, 342(25):
433-434.
Paerl, H. W. and Otten, T. G. 2013b. Harmful Cyanobacterial Blooms: Causes, Consequences,
and Controls. Microbial Ecology. 65: 995-1010.
Prepas, E. E., Kotak, B. G., Campbell, L. M., Evans, J. C., Hrudey, S. E. and Holmes, C. F. B.
1997. Accumulation and elimination of cyanobacterial hepatotoxins by the freshwater clam
Anodonta grandis simpsoniana. Canadian Journal of Fisheries and Aquatic Sciences, 54: 41-
46.
Puschner, B., Hoff, B. and Tor, E. R. 2008. Diagnosis of anatoxin-a poisoning in dogs from
North America. Journal of Veterinary Diagnostic Investigation, 20: 89-92.
Rai, A.N. 1990. CRC Handbook of Symbiotic Cyanobacteria. CRC Press, Boca Raton, 253 pp.
Rellan, S., Osswald, J., Saker, M., Gago-Martinez, A. and Vasconcelos, V. 2009. First detection
of anatoxin-a in human and animal dietary supplements containing cyanobacteria. Food and
Chemical Toxicology, 47: 2189-2195.
Reynolds, C. S. 2006. The Ecology ofPhytoplankton. Cambridge University Press, Cambridge.
Rice, D. and Barone Jr, S. 2000. Critical periods of vulnerability for the developing nervous
system: Evidence from humans and animal models. Environmental Health Perspectives, 108
(Suppl. 3): 511-533.
Robarts, R. D. and Zohary, T. 1987. Temperature effects on photosynthetic capacity, respiration,
and growth rates of bloom-forming cyanobacteria. New Zealand Journal of Marine and
Freshwater Research, 21: 391-399.
Rogers, E. H., Hunter III, E. S., Rosen, M. B., et al. 2003. Lack of evidence for intergenerational
reproductive effects due to prenatal and postnatal undernutrition in the female CD-I mouse.
Reproductive Toxicology, 17(5): 519-525.
Health Effects Support Document for Anatoxin-a - June 2015
41
-------
Rogers, E. H., Hunter III, E. S.,Moser, V. C., et al. 2005. Potential developmental toxicity of
anatoxin-a, a cyanobacterial toxin. Journal of Applied Toxicology, 25(6): 527-534.
Rowell, P. P. and Wonnacott, S. 1990. Evidence for functional activity of up-regulated nicotine
binding sites in rat striatal synaptosomes. Journal of Neurochemistry, 55(6): 2105-2110.
Rymuszka A, Sieroslawska A. 2010. Study on apoptotic effects of neurotoxin anatoxin-a on fish
immune cells. Neuroendocrinology Letters, 31 (Suppl 2): 11-5.
Sarma, T. A. 2013. Cyanobacterial Toxins in Handbook of Cyanobacteria. CRC Press. Taylor
and Francis Group, pp. 487-606.
Scheffer, M., Rinaldi, S., Gragnani, A., Mur, L.R. and Van Nes, E.H. 1997. On the dominance
of filamentous cyanobacteria in shallow turbid lakes. Ecology, 78: 272-282.
Schindler, D. W., Hecky, R. E., Findlay D. L., et al. 2008. Eutrophication of lakes cannot be
controlled by reducing nitrogen input: results of a 37-year whole-ecosystem experiment.
Proceedings of the National Academy of Sciences of the United States of America, 105,
11254-11258.
Schwimmer, M. and Schwimmer, D. 1968. Medical aspects of phycology. In: D. F. Jackson,
(Ed.). Algae, Man, and the Environment. Syracuse University Press, New York, NY. p. 279-
358.
Shapiro, J. 1984. Blue-green dominance in lakes: the role and management significance of pH
and CO2. Internationale Revue der Gesamten Hydrobiologie, 69, 765-780.
Sieroslawska, A. and Rymuszka, A. 2010. Evaluation of genotoxic potential of neurotoxin
anatoxin-a with the use of umuC test. Neuroendocrinology Letters, 31 (Suppl 2): 16-20.
Siren, A. and Feuerstein, G. 1990. Cardiovascular effects of anatoxin-a in the conscious rat.
Toxicology and Applied Pharmacology, 102(1): 91-100.
Skulberg, O. M. 1996. Terrestrial and limnic algae and cyanobacteria. In: A. Elvebakk and P.
Prestrud (Eds.). A Catalogue of SvalbardPlants, Fungi, Algae and Cyanobacteria. Part 9,
Norsk Polarinstitutt Skrifter 198:383-395.
Smith, V. H. 1983. Low nitrogen to phosphorus ratios favor dominance by blue-green algae in
lake phytoplankton. Science, 221(4611): 669-671.
Smith, V.H. 1986. Light and nutrient effects on the relative biomass of blue-green algae in lake
phytoplankton. Canadian Journal of Fisheries and Aquatic Sciences, 43, 148-153.
Smith, C., and Sutton, A. 1993. Persistence of Anatoxin-a in Reservoir Water. FWR Report No
FR0427. Retrieved on Februray 25, 2015 from the World Wide Web
www. fwr. org/ waterq/fr0427. htm
Health Effects Support Document for Anatoxin-a - June 2015
42
-------
Soliakov, L., Gallagher, T. and Wonnacott, S. 1995. Anatoxin-a evoked 3H dopamine release
from rat striatal synaptosomes. Neuropharmacology. 34(11): 1535-1541.
Spivak, C. E. and Albuquerque, E. X. 1982. Dynamic properties of the nicotinic acetylcholine
receptor ionic channel complex: Activation and Blockade. In: I. Hanin and A.M. Goldberg,
(Eds.). Progress in Cholinergic Biology: Model Cholinergic Synapses. Raven Press, New
York, NY. 6 p. 323-357.
Spivak, C. E., Waters, J., Witkop, B. and Albuquerque, E. X. 1983. Potencies and channel
properties induced by semirigid agonists at frog nicotinic acetylcholine receptors. Molecular
Pharmacology, 23: 337-343.
Stevens, D. K. and R. I. Krieger. 1990. N-Methylation of anatoxin-a abolishes nicotinic cholinergic
activity. Toxicon, 28(2): 133-134.
Stevens, D. K. and Krieger, R. I. 1991a. Stability studies on the cyanobacterial nicotinic alkaloid
anatoxin-a. Toxicon, 29: 167-179.
Stevens, D. K. and Krieger, R. I. 1991b. Effect of route of exposure and repeated doses on the
acute toxicity in mice of the cyanobacterial nicotinic alkaloid anatoxin-a. Toxicon, 29(1):
134-138.
Stewart, I, Schluter, P. J., & Shaw, G. R. 2006. Cyanobacterial 1 ipopolysaccharides and human
health-a review. Environmental Health, 5(1): 7.
Stewart I., Seawright A., and Shaw G. 2008. Cyanobacterial Harmful Algal Blooms: State of the
Science and Research Needs. Advances in Experimental Medicine and Biology, 619: 613—
637.
Swanson, K. L., Allen, C. N., Aronstam, R. S., Rapoport, H. and Albuquerque, E. X. 1986.
Molecular mechanisms of the potent and stereospecific nicotinic receptor agonist (+)-
anatoxin-a. Molecular Pharmacology, 29: 250-257.
Swanson, K. L., Aracava, Y., Sardina, F. J., Rapoport, H., Aronstam, R. S. and Albuquerque, E.
X. 1989. N-Methylanatoxinol isomers: Derivatives of the agonist (+)-anatoxin-a block the
nicotinic acetylcholine receptor ion channel. Molecular Pharmacology, 35(2): 223-231.
Swanson, K. L., Aronstam, R. S., Wonnacott, S., Rapoport, H. and Albuquerque, E. X. 1991.
Nicotinic pharmacology of anatoxin analogs. Side chain structure-activity relationships at
peripheral agonist and noncompetitive antagonist sites. Journal of Pharmacology and
Experimental Therapeutics, 259(1): 377-386.
Taylor, P. 1996. Anticholinesterase agents. In: M.J. Wonsiewicz and P. McCurdy, (Eds.).
Goodman and Oilman's The Pharmacological Basis of Therapeutics, McGraw Hill, New
York, NY. p. 161-176.
Health Effects Support Document for Anatoxin-a - June 2015
43
-------
Teixeira-de Mello, F., Meerhoff, M., Pekcan-Hekim, Z. and Jeppesen, E. 2009. Substantial
differences in littoral fish community structure and dynamics in subtropical and temperate
shallow lakes. Freshwater Biology, 54: 1202-1215.
Thomas, P., Stephens, M., Wilkie, G., et al. 1993. (+)-Anatoxin-a is a potent agonist at neuronal
nicotinic acetylcholine receptors. Journal of Neurochemistry. 60(6): 2308-2311.
Toxicology Literature Online (TOXLINE) 2012. Toxicology Data Network, National Institute
of Health. Retrieved on September 25, 2012 from the World Wide Web:
http://toxnet.nlm.nih.gov/cgi-bin/sis/htmlgen7TOXLINE
U.S. EPA (United States Environmental Protection Agency). 1986a. Guidelines for the Health
Risk Assessment of Chemical Mixtures. Fed. Reg. 51(185):34014-34025. Available from:
http://cfpub.epa.gov/ncea/cfm/recordisplay.cfm?deid=22567
U.S. EPA (United States Environmental Protection Agency). 1986b. Guidelines for Mutagenicity
Risk Assessment. Fed. Reg. 51(185):34006-34012. Available from:
http://cfpub.epa.gov/ncea/cfm/recordisplay.cfm?deid=23 160
U.S. EPA (United States Environmental Protection Agency). 1988. Recommendations for and
documentation of Biological Values for Use in Risk Assessment. EPA 600/6-87/008.
Available from: National Technical Information Service, Springfield, VA; PB88-179874/AS.
Available from: http://cfpub.epa.gov/ncea/cfm/recordisplay.cfm?deid=34855
U.S. EPA (United States Environmental Protection Agency). 1991. Guidelines for
Developmental Toxicity Risk Assessment. Fed. Reg. 56(234):63798-63826. Available from:
http://cfpub.epa.gov/ncea/cfm/recordisplay.cfm?deid=23 162
U.S. EPA (United States Environmental Protection Agency). 1994a. Interim policy for particle
size and limit concentration issues in inhalation toxicity studies. Fed. Reg. 59(206):53799.
Available from: http://cfpub.epa.gov/ncea/cfm/recordisplay.cfm7deidH86068
U.S. EPA (United States Environmental Protection Agency). 1994b. Methods for derivation of
inhalation reference concentrations and application of inhalation dosimetry. EPA/600/8-
90/066F. Available from: National Technical Information Service, Springfield, VA; PB2000-
500023, and http://vvvvvv.epa.gov/iris/backgrd.htm 1
U.S. EPA (United States Environmental Protection Agency). 1995. Use of the benchmark dose
approach in health risk assessment. U.S. Environmental Protection Agency. EPA/630/R-
94/007. Available from: National Technical Information Service, Springfield, VA; PB95-
213765, and http://vvvvvv.epa. gov/i ri s/backgrd. htm 1
U.S. EPA (United States Environmental Protection Agency). 1996. Guidelines for reproductive
toxicity risk assessment. Fed. Reg. 61(212):56274-56322. Available from:
http://vvvvvv.epa.gov/iris/backgrd.html
Health Effects Support Document for Anatoxin-a - June 2015
44
-------
U.S. EPA (United States Environmental Protection Agency). 1998. Guidelines for neurotoxicity
risk assessment. Fed Reg 63(93):26926-26954. Available from:
http://vvvvvv.epa.gov/iris/backgrd.html
U.S. EPA (United States Environmental Protection Agency). 2000a. Science Policy Council
Handbook: peer review. 2nd edition. Prepared by the Office of Science Policy, Office of
Research and Development, Washington, DC. EPA 100-B-00-001. Available from:
http://vvvvvv.epa.gov/iris/backgrd.html.
U S. EPA (United States Environmental Protection Agency). 2000b. Supplemental guidance for
conducting for health risk assessment of chemical mixtures. EPA/630/R-00/002. Available
from: http://vvvvvv.epa.gov/iris/backgrd.html.
U.S. EPA (United States Environmental Protection Agency). 2002. A review of the reference
dose and reference concentration processes. Risk Assessment Forum, Washington, DC;
EPA/630/P-02/0002F. Available from: http://www.epa.gov/iris/backgrd.html
U.S. EPA (United States Environmental Protection Agency). 2005a. Guidelines for carcinogen
risk assessment. Risk Assessment Forum, Washington, DC; EPA/630/P-03/001B. Available
from: http ://vvvvvv. epa. gov/i ri s/backgrd.html
U.S. EPA (United States Environmental Protection Agency). 2005b. Supplemental guidance for
assessing susceptibility from early-life exposure to carcinogens. Risk Assessment Forum,
Washington, DC; EPA/630/R-03/003F. Available from:
http://vvvvvv.epa.gov/iris/backgrd.html
U.S. EPA (United States Environmental Protection Agency). 2006a. Science Policy Council
Handbook: Peer Review. 3rd edition. Prepared by the Office of Science Policy, Office of
Research and Development, Washington, DC. EPA 100-B-06-002. Available from:
http://vvvvvv.epa.gov/peerrevievv/pdfs/peer_revievv_handbook_2012.pdf
U.S. EPA (United States Environmental Protection Agency). 2006b. A framework for assessing
health risks of environmental exposures to children. National Center for Environmental
Assessment, Washington, DC; EPA/600/R-05/093F. Available from:
http://vvvvvv.epa.gov/iris/backgrd.html
U.S. EPA (United States Environmental Protection Agency). 2011 Exposure Factors Handbook
2011 Edition (Final). Washington, DC, EPA/600/R-09/052F. Available from:
http://www.epa.gov/ncea/efh/pdfs/efh-complete.pdf
U.S. EPA (United States Environmental Protection Agency). 2012. Benchmark dose technical
guidance document [external review draft], EPA/630/R-00/001. Available from:
http://vvvvvv.epa.gov/iris/backgrd.html
Health Effects Support Document for Anatoxin-a - June 2015
45
-------
U.S. EPA. (United States Environmental Protection Agency). 2014a. Child-Specific Exposure
Scenarios Examples (Final Report), Washington, DC, EPA/600/R-14-217F. Available from:
http://cfpub.epa.gov/ncea/risk/recordisplay.cfm?deid=26221 1 #Download
U.S. EPA (United States Environmental Protection Agency). 2014b. Framework for Human
Health Risk Assessment to Inform Decision Making. Office of the Science Advisor, Risk
Assessment Forum, Washington, DC; EPA/100/R-14/001. Available from:
http://vvvvvv2.epa.gov/programs-office-science-advisor-osa/framevvork-human-health-risk-
assessment-inform-decision-making
Valentine, W. M., Schaeffer, D. J. and Beasley, V. R. 1991. Electromyographic assessment of
the neuromuscular blockade produced in vivo by anatoxin-a in the rat. Toxicon, 29(3): 347-
357.
Viaggiu, E., Melchiorre, S., Volpi, F., et al. 2004. Anatoxin-a toxin in the cyanobacterium
Planktothrix rubescens from a fishing pond in northern Italy. Environmental Toxicology
19(3): 191-197.
Wagner, C., and Adrian, R. 2009. Cyanobacteria dominance: quantifying the effects of climate
change. Limnology and Oceanography, 54: 2460-2468.
Wang, X., Parkpian, P., Fujimoto, N., Ruchirawat, K.M., DeLaune, R.D., and Jugsujinda,
A. 2002. Environmental conditions associated with microcystins production to Microcystis
aeruginosa in a reservoir of Thailand. Journal of Environmental Science and Health, Part
Part A, 37: 1181-1207.
Watanabe, M. F. and Oishi, S. 1985. Effects of environmental factors on toxicity of a
cyanobacterium Microcystis aeruginosa under culture conditions. Applied Environmental
Microbiology, 49: 1342-1344.
Watanabe, M. M., Kaya, K. and Takamura, N. 1992. Fate of the toxic cyclic heptapeptides, the
microcystins, from blooms of Microcystis (cyanobacteria) in a hypertrophic lake. Journal of
Phycology, 28: 761-767.
Watanabe, M. F., Park, H-D., Kondo, F., Harada, K-I., Hayashi, H. and Okino, T. 1997.
Identification and estimation of microcystins in freshwater mussels. Natural Toxins, 5: 31-35.
Weyhenmeyer, G. A. 2001. Warmer winters: are planktonic algal populations in Sweden's
largest lakes affected? Ambio, 30: 565-571.
WHO (World Health Organization). 1999. Toxic Cyanobacteria in Water: A Guide to their
Public Health Consequences, Monitoring, and Management, I. Chorus and J. Bartram, Eds.
E&FN Spon, London, UK .
Health Effects Support Document for Anatoxin-a - June 2015
46
-------
WHO (World Health Organization). 2003. Cyanobacterial toxins: Microcystin-LR in Drinking-
water. Background document for development of WHO Guidelines for Drinking-water
Quality, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland.
Wonnacott, S., Jackman, S., Swanson, K. L, Rapoport, H., and Albuquerque, E. X. 1991.
Nicotinic pharmacology of anatoxin analogs. Side chain structure-activity relationships at
neuronal nicotinic ligand binding sites. Journal of Pharmacology and Experimental
Therapeutics, 259(1): 387-391.
Wonnacott, S., Kaiser, S., Mogg, A., Soliakov, L. and Jones, I. W. 2000. Presynaptic nicotinic
receptors modulating dopamine release in the rat striatum. European Journal of
Pharmacology, 393(1/3): 31-38.
Wonnacott, S. and Gallagher, T. 2006. The chemistry and pharmacology of anatoxin-a and
related homotropanes with respect to nicotinic acetylcholine receptors. Marine Drugs, 4:
228-254.
WSDE (Washington State Department of Ecology). 2012. Freshwater Algae Control
Program. Accessed December 12, 2012;
http://www.ecy.wa.gov/programs/wq/plants/algae/index.html
Yang, X. 2007. Occurrence of the cyanobacterial neurotoxin, anatoxin-a, in New York State
waters. State Unversity of New York, College of Environmental Science and Forestry, 245
pp. UMI Number 3290535.
Yavasoglu, A., Karaaslan, M. A., et al. 2008. Toxic effects of anatoxin-a on testes and sperm
counts of male mice. Experimental And Toxicologic Pathology: Official Journal Of The
Gesellschaft Fur Toxikologische Pathologie 60(4-5): 391-396.
Zhang, X., Stjernlof, P., Adem, A., and Nordberg, A. 1987. Anatoxin-a a potent ligand for
nicotinic cholinergic receptors in rat brain. European Journal of Pharmacology, 135: 457-
458.
47
Health Effects Support Document for Anatoxin-a - June 2015
------- |